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Supplementary Methods 
 
 
General experimental  
 
1
H NMR spectra were recorded on Bruker DPX 200 (200 MHz), Bruker AVIIIHD 400 nanobay 
(400 MHz), Bruker AVII 500 (500 MHz) with dual 
13
C(
1
H) cryoprobe, or Bruker AVIIIHD 500 (500 MHz) 
spectrometer in the stated solvents as a reference for the internal deuterium lock. The chemical shift data for 
each signal are given as δH in units of parts per million (ppm) relative to tetramethylsilane (TMS) where δH 
(TMS) = 0.00 ppm. The spectra are calibrated using the solvent peak with the data provided by Fulmer et al
1
. 
The multiplicity of each signal is indicated by s (singlet); br s (broad singlet); d (doublet); dd (doublet of 
doublets), ddd (doublet of doublet of doublets), t (triplet), q (quartet), dq (double of quartet) or m (multiplet). 
The number of protons (n) for a given resonance signal is indicated by nH. Where appropriate, coupling 
constants (J) are quoted in Hz and are recorded to the nearest 0.1 Hz. Identical proton coupling constants (J) 
are averaged in each spectrum and reported to the nearest 0.1 Hz. The coupling constants are determined by 
analysis using Bruker TopSpin version 3.2 software. 
1
H spectra were assigned using 2D NMR experiments 
including COSY, HMBC, HSQC, 
29
Si-
1
H HMBC and 
31
P-
1
H HMBC. 
13
C NMR spectra were recorded on a 
Bruker AVIIIHD 400 nanobay (101 MHz), or Bruker AVII 500 (126 MHz) spectrometer, with dual 
13
C(
1
H) 
cryoprobe, in the stated solvents, with broadband proton decoupling and an internal deuterium lock. The 
chemical shift data for each signal are given as δC in units of parts per million (ppm) relative to 
tetramethylsilane (TMS) where δC (TMS) = 0.00 ppm. The spectra are calibrated using the solvent peak with 
the data provided by Fulmer et al
1
. The shift values of resonances are quoted to 1 decimal place unless peaks 
have similar chemical shifts, in which case 2 decimal places are used. 
13
C spectra were assigned using 2D 
NMR experiments including HMBC and HSQC. When two diastereoisomers are present in the sample, A and 
B denotes each of the two diastereoisomers without distinguishing between them. A is arbitrarily assigned to 
the diastereoisomer with the highest ppm shift and B to the diastereoisomer with the lowest ppm shift, in 
1
H NMR and 
13
C NMR spectra.  
Low resolution electrospray ionisation mass spectra were acquired on a Waters LCT Premier 
spectrometer or Agilent 6120 Quadrupole spectrometer. High resolution mass spectra were recorded on a 
 3 
Bruker MicroTOF spectrometer, operating in positive or negative mode, as indicated, from solutions of 
MeOH, MeCN or H2O. m/z values are reported in Daltons and followed by their percentage abundance in 
parentheses. Electron ionisation/field ionisation (EI/FI) was carried out on a Waters GCT with a temperature 
programmed solids probe inlet. MALDI was carried out on a Waters MALDI Micro MX. When a compound 
was not observed by LRMS, only HRMS is quoted.  
Specific optical rotations were measured using either a Perkin Elmer Model 241 polarimeter or 
Schmidt + Haensch UniPol L2000 polarimeter, in cells with a path length of 1 dm, using a sodium lamp at 
589 nm. The concentration (c) is expressed in g/100 mL (equivalent to g/0.1 dm
3
). Specific rotations are 
denoted [𝛼]𝐷
𝑇  and are given in implied units of 10−1degcm2g−1 at the temperature stated. Melting points were 
determined using a Leica Galen III hot stage microscope and are uncorrected. The solvents of crystallisation 
are shown in parentheses. Infrared (IR) spectra were obtained from neat samples, either as liquids or solids 
using a diamond ATR module. The spectra were recorded on a Bruker Tensor 27 spectrometer. Absorption 
maxima are reported in wavenumbers (cm
−1
) and reported as s (strong), m (medium), w (weak) or br (broad). 
Only the main, relevant peaks have been assigned. 
Thin layer chromatography (TLC) was carried out on normal phase Merck silica gel 60 F254 
aluminium-supported chromatography sheets. Visualisation was by absorption of UV light (λmax 254 nm), 
exposure to iodine vapour or thermal development after dipping in either an ethanolic solution of ninhydrin or 
an aqueous solution of potassium permanganate.  
Normal phase silica gel flash column chromatography was performed either manually using VWR 
Prolabo silica gel 60 (240–400 mesh) under a positive pressure of nitrogen or on a Biotage SP1 automated 
column chromatography system using KP-Sil
®
 SNAP Flash Silica Cartridges. 
Chemicals were purchased from Acros UK, Apollo Scientific, Enamine, Sigma Aldrich UK, Alfa 
Aesar UK, Fisher Scientific UK, Fluka UK, Fluorochem, Merck, Argo International Limited and TCI-Europe. 
All reagents were purified, when necessary, by standard techniques
2
. In particular, Et3N and pyridine were 
dried by stirring over solid KOH pellets overnight followed by fractional distillation. DIPA was distilled from 
NaH. These were stored under Ar and over 3 Å molecular sieves. Anhydrous solvents were obtained under the 
following conditions: Et2O, toluene and CH2Cl2 were dried by passing through a column of activated basic 
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alumina according to the Grubbs’ procedure.3Anhydrous DMF, DMSO, MeOH and MeCN were purchased 
from Sigma Aldrich UK in SureSeal™ bottles and used without further purification. Anhydrous THF was 
distilled from sodium metal, using benzophenone as an indicator
2
. All other solvents were used as supplied 
(analytical or HPLC grade) without purification. 
In vacuo refers to the removal of solvents under reduced pressure using a Büchi™ rotary evaporator 
in a water bath at 40 °C, unless otherwise stated. Where appropriate and if not otherwise stated, all non-
aqueous reactions were performed in a flame dried flask under an inert atmosphere. Hexane refers to a 
mixture of hexane isomers and petroleum ether refers to the fraction of light petroleum ether boiling within 
the range of 40–60 °C. Brine refers to a saturated aqueous solution of sodium chloride. Rochelle’s salt refers 
to an aqueous solution of potassium sodium tartrate tetrahydrate. Lyophilisation refers to the removal of H2O 
from aqueous solutions by freeze drying using a CHRIST Alpha 1-2 LD lyophiliser. Celite
®
 refers to Celite
®
 
545 filter aid, treated with sodium carbonate, flux-calcined which was purchased from Sigma Aldrich. Glass 
microfiber filter refers to Whatman
®
 borosilicate glass microfiber filters, Grade GF/B. 
Compound purity was determined by analytical high-performance liquid chromatography (HPLC) on 
a PerkinElmer Flexar system with a Binary LC Pump and UV/VIS LC Detector using:  
a) a reversed phase Dionex Acclaim
®
 120 column (C18, 5 μm, 4.6 × 150 mm) with H2O/MeCN/TFA 95:5:0.1 
(A) and MeCN/ H2O/TFA 95:5:0.1 (B) or H2O/MeCN 95:5 (A) and MeCN/H2O 95:5 (B) as eluents; or b) a 
normal phase HyperSil GOLD™ Silica column (5 μm, 4.6 × 150 mm) with heptane (A) and IPA (B) as 
eluents. Gradient methods of 19 to 25 minutes were employed with a constant flow rate, and detection at 254 
nm (Methods 1, 2 and 3). Samples were injected by dissolving in the relevant solvent system. The methods 
used are described below: 
Method 1 (Reversed Phase HPLC gradient Supplementary Table 6): A = H2O/MeCN/TFA 95:5:0.1; B = 
MeCN/ H2O/TFA 95:5:0.1; 1.0 mL.min
−1
; 254 nm.  
Method 2 (Reversed Phase HPLC gradient Supplementary Table 6): A = H2O/MeCN 95:5; B = MeCN/ H2O 
95:5; 1.0 mL.min
−1
; 254 nm. 
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Method 3 (Normal Phase HPLC gradient Supplementary Table 7): Normal Phase; A = Heptane; B = IPA; 
1.0 mL.min
−1
; 254 nm. 
Enantiomeric purity was determined by chiral analytical high-performance liquid chromatography 
(HPLC) on a PerkinElmer Flexar system with a Binary LC Pump and UV/VIS LC Detector using a 
ChiralPak
®
 AD-H column (5 μ m, 4.6 × 150 mm) with IPA (A) and heptane (B) as eluents. Isocratic methods 
of 45 minutes were employed with a constant flow rate of 1.0 mL.min
−1
 or 0.8 mL.min
−1
 and detection at 220 
or 254 nm as indicated. Samples were injected by dissolving in the relevant solvent system. The enantiomeric 
excess (e.e) was determined using the following equation: e.e. = ((R−S)/R+S)) ⨉ 100 where R and S stand for 
the individual enantiomers and R + S = 1. 
GC-MS analysis was performed at two sites: the University of Oxford Department of Plant Sciences 
(Oxford, UK), or the John Innes Centre (Norwich, UK). GC-MS analysis of nodule tissues and in vitro assays 
were performed at the University of Oxford Department of Plant Sciences using an Agilent 7989 GC coupled 
to an Agilent 5975 quadrupole MS detector, electron 702 impact ionisation (70 eV) equipped with an Agilent 
CP9013 column (30 mm, 0.25 mm inner diameter).  Analysis was performed with a 0.6 mL/min constant 
helium flow with the following oven temperatures: 150 °C for 2 min, ramped to 300 °C at 5 °C per min, then 
ramped to 330 °C at 10 °C per min, then dropped to 150 °C at 150 °C per min, and held for 1 min. The front 
inlet, source and transfer line temperature were set throughout at 230 °C, 250°C and 250 °C respectively 
(LJS_TMSI protocol). Alternatively, the following oven temperatures were used for the LJS_Golm Stardard 
protocol: 70 °C for 5 min, ramped to 350 °C at 5 °C per min, then dropped to 330 °C at 120 °C per min, held 
for 5 min, then dropped to 70 °C at 120 °C per min, and held for 1 min. The front inlet, source and transfer 
line temperature were set throughout at 230 °C, 250°C and 250 °C respectively. GC-MS of engineered plant 
tissues was performed at the John Innes Centre (Eng_Plant protocol). A 1 µl derivatised sample was injected 
into a ZB-5HT column (Phenomenex, 35 m x 0.25 mm internal diameter, 0.25 µm film) in Agilent 7890B GC 
machine and operated at a constant helium flow of 1 ml per min.  The oven temperature program used was as 
follows: 100 °C for 1 min, ramped to 200 °C at 20 °C per min, held at 200 °C for 3 min, ramped to 300 °C at 
30 °C per min and held at 300 °C for 2 min. The front inlet, source and transfer line temperature were set 
throughout at 250 °C, 230 °C and 280 °C respectively. NISTv2.2 library was used to assign identity to peaks 
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in the GC-MS chromatogram. SIA and 3-O-MSI were identified based on the comparison of retention times 
and mass spectra to chemical standards synthesised in this work. GC-MS data were analysed using 
MassHunter Qualitative Analysis software (Agilent) or MSD Chemstation Enhanced Chemstation software 
(Agilent). 
 
Synthetic protocol and characterisation data for myo-inositol 1,3,5-orthoformate (8) 
       (8) 
To a solution of myo-inositol 3 (20.0 g, 111 mmol, 1.0 eq) in DMF (80 mL) were added 
triethylorthoformate (82.5 g, 555 mmol, 5.0 eq) and PTSA∙H2O (8.45 g, 44.5 mmol, 0.40 eq). The reaction 
mixture was stirred at 105 °C for 3 days, then allowed to cool to RT. The solution was neutralised by addition 
of solid NaHCO3 (10 g). The volatile components were removed in vacuo to give a yellow paste which was 
taken up in MeOH (300 mL). The mixture was cooled to −20 °C for 13 hours, then filtered to remove excess 
solid NaHCO3 and sodium tosylate by-products. The filtrate was concentrated in vacuo to give a brown oil 
which was taken up in MeOH (50 mL) and cooled to −20 °C for 2 days. The resulting colourless crystalline 
solid was isolated by filtration, washed with CHCl3 (25 mL), and dried. The remaining filtrate was 
concentrated in vacuo and purified by column chromatography over silica gel (CH2Cl2/MeOH 9.5:0.5) to give 
another batch of the crystalline solid. The combined materials provided 8 (14.9 g, 65%): mp: 300–302 °C 
(lit.
4,5
 300–302 °C); TLC (MeCN:EtOAc, 8:2 v/v): Rf = 0.40; 
1
H NMR (400 MHz; D6-DMSO): δ 5.48 (br s, 
1H, C(2)OH), 5.44–5.36 (m, 2H, C(4)OH and C(6)OH), 5.31 (d, J = 6.2 Hz, 1H, H-7) 4.31–4.24 (dd, J = 3.9, 
3.9 Hz, 2H, H-1 and H-3), 4.09–4.04 (m, 1H, H-5), 4.02–3.98 (m, 1H, H-2), 3.97–3.92 (m, 2H, H-4 and H-6); 
13
C NMR (101 MHz; D6-DMSO): δ 101.9 (C-7), 74.4 (C-1, C-3), 69.3 (C-5), 67.5 (C-4, C-6), 58.6 (C-2); 
LRMS (m/z): [M+H]
+ 
191.2. These data are in good agreement with the literature values
4,5
.  
1
2
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Synthetic protocol and characterisation data for 4,6-di-O-benzyl-myo-inositol 1,3,5-orthoformate (9) 
(9) 
LiH (167 mg, 21.0 mmol, 4.0 eq) was gradually added to a solution of 8 (1.00 g, 5.26 mmol, 1.0 eq) 
in anhydrous DMF (15 mL), and the resulting solution was stirred at RT for 30 minutes. Benzyl bromide 
(1.44 mL, 12.1 mmol, 2.3 eq) was then added dropwise and the solution was stirred for a further 48 hours. 
After quenching the reaction with H2O (30 mL), the aqueous phase was extracted with EtOAc (3 × 30 mL). 
The combined organic layers were washed with H2O (4 × 30 mL), and brine (2 × 30 mL), then dried 
(MgSO4), filtered, and concentrated in vacuo. The residue obtained was filtered through a short plug of silica 
gel (Petroleum ether/EtOAc 6:4) then crystallised (EtOAc) to yield 9 (1.37 g, 71%) as a colourless solid: mp: 
123–124 °C (lit.6 122–124 °C; lit.7 124–125 °C); TLC (Petroleum ether:EtOAc, 1:1 v/v): Rf = 0.48; 
1
H NMR 
(400 MHz; CDCl3): δ 7.31–7.26 (m, 10H, H-10 to H-14 and H-17 to H-21), 5.47 (d, J = 1.0 Hz, 1H, H-7), 
4.67 (d, JAB = 11.5 Hz, 2H, H-8 and H-15), 4.59 (d, JAB = 11.5 Hz, 2H, H-8’ and H-15’), 4.48–4.45 (m, 1H, 
H-2), 4.38 (dd, J = 3.7, 3.7 Hz, 2H, H-4 and H-6), 4.25–4.18 (m, 3H, H-1, H-3 and H-5), 3.04 (d, J = 11.5 Hz, 
1H,  C(2)OH); LRMS (m/z): [M+Na]
+
 393.1. These data are in good agreement with the literature values
5–8
.  
Synthetic protocol and characterisation data for 2-O-allyl-4,6-di-O-benzyl-myo-inositol 1,3,5-
orthoformate (10) 
(10) 
A solution of 9 (800 mg, 2.36 mmol, 1.0 eq) in anhydrous DMF  (14 mL) was cooled to 0 °C and 
NaH (170 mg, 7.09 mmol, 3.0 eq, 60% dispersion in mineral oil) was added portionwise over 5 minutes. The 
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reaction mixture was left to stir at 0 °C for 10 minutes, then warmed to RT, and stirred for a further 30 
minutes. After addition of allyl bromide (0.614 mL, 7.09 mmol, 3.0 eq) at 0 °C, followed by stirring for 10 
minutes, the reaction mixture was warmed to RT, and left to stir for a further 17 hours. The reaction was then 
quenched with H2O (5 ml) and diluted in EtOAc (5 mL). The aqueous phase was extracted with EtOAc (4 × 
10 mL), and the combined organic layers were washed with H2O (2 × 10 mL), and brine (2 × 10 mL), then 
dried (MgSO4), filtered, and concentrated in vacuo. Purification by column chromatography over silica gel 
(Petroleum ether/EtOAc 9:1, 8:2, 7:3, 6:4, 5:5) afforded 10 (893 mg, 92%) as a thick colourless oil: TLC 
(Petroleum ether:EtOAc, 1:1 v/v): Rf  = 0.73; 
1
H NMR (400 MHz; CDCl3): δ 7.35–7.27 (m, 10H, H-10 to H-
14 and H-17 to H-21), 6.04–5.91 (m, 1H, H-23), 5.53 (s, 1H, H-7), 5.35–5.27 (m, 1H, H-24), 5.24–5.18 (m, 
1H, H-24’), 4.69 (d, JAB = 11.7 Hz, 2H, H-8 and H-15), 4.57 (d, JAB = 11.7 Hz, 2H, H-8’ and H-15’), 4.49–
4.43 (m, 1H, H-5), 4.40–4.35 (m, 2H, H-4 and H-6), 4.35–4.31 (m, 2H, H-1 and H-3), 4.14–4.09 (ddd, 2H, 
JXY = 5.6, 1.3, 1.3 Hz, H-22 and H-22’), 3.98–4.02 (m, 1H, H-2); IR (thin film): 3384 (O-H) (br), 3064 (w), 
3030 (w), 2970 (br), 2961 (w), 1497 (w), 1454 (w), 1377 (w), 1306 (w), 1207 (w), 1164 (s), 1139 (m), 1098 
(s), 996 (s), 950 (m), 933 (m), 896 (m), 820 (w), 739 (m), 699 (m) cm
−1
; LRMS (m/z): [M+H]
+
 411.2. These 
data are in good agreement with the literature values
9
.  
Synthetic protocol and characterisation data for 2-O-allyl-4,6-di-O-benzyl-myo-inositol (11) 
(11) 
To a solution of 10 (893 mg, 2.18 mmol, 1.0 eq) in MeOH (2.2 mL) was added PTSA∙H2O (414 mg, 
2.18 mmol, 1.0 eq). The reaction mixture was stirred at RT for 16 hours and quenched with Et3N (304 µL, 
2.18 mmol, 1.0 eq). The solution was concentrated in vacuo, and the residue obtained was purified by column 
chromatography over silica gel (Petroleum ether/EtOAc 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8) to give 11 (822 mg, 
94%) as a colourless oil: TLC (EtOAc): Rf  = 0.34; 
1
H NMR (500 MHz; CDCl3): δ 7.40–7.35 (m, 8H, H-12, 
H-13, H-15, H-16, H-19, H-20, H-22 and H-23), 7.34–7.29 (m, 2H, H-14 and H-21), 5.94 (dddd, J = 17.2, 
12
3 4
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10.4, 5.5, 5.5 Hz, 1H, H-8), 5.28 (dddd, JXY = 17.2, 1.8, 1.7, 1.7 Hz, 1H, H-9), 5.20 (dddd, JXY = 10.4, 1.8, 1.4, 
1.4 Hz, 1H, H-9’), 4.89 (d, JAB = 11.4 Hz, 2H, H-10 and H-17), 4.86 (d, JAB = 11.4 Hz, 2H, H-10’ and H-17’), 
4.33 (ddd, JXY = 5.5, 1.7, 1.4 Hz, 2H, H-7 and H-7’), 3.90 (dd, J 2.8, 2.8 Hz, 1H, H-2), 3.64 (dd, J = 9.4, 9.4 
Hz, 2H, H-4 and H-6), 3.57–3.50 (m, 3H, H-1, H-3 and H-5), 2.53 (d, J = 1.9 Hz, 1H, C(5)OH), 2.42 (s, 1H, 
C(1)OH), 2.41 (s, 1H, C(3)OH); 
13
C NMR (126 MHz; CDCl3): δ 138.6 (C-11, C-18), 135.0 (C-8), 128.8, 
128.2, 128.1 (C-12 to C-16 and C-19 to C-23), 117.2 (C-9), 82.2 (C-4, C-6), 79.3 (C-2), 75.2 (C-10, C-17), 
75.1 (C-5), 74.4 (C-7), 72.6 (C-1, C-3); IR (thin film): 3545 (O-H) (br), 3444 (O-H) (br), 3031 (w), 2981 (w), 
2884 (w), 1497 (w), 1398 (w), 1364 (w), 1251 (w), 1211 (w), 1115 (s), 1061 (s), 1030 (s), 1002 (s), 930 (m), 
732 (s), 697 (s) cm
−1
; LRMS (m/z): [M+Na]
+
 423.2; HRMS (m/z): [M+H]
+
 calcd. for C23H29O6, 401.19587; 
found 401.19523. These data are in good agreement with the literature values
8,10
.  
Synthetic protocol and characterisation data for 2-O-allyl-1,3,4,5,6-penta-O-benzyl-myo-inositol (12) 
(12) 
A solution of 11 (786 mg, 1.96 mmol, 1.0 eq) in DMF (16 mL) was cooled to 0 °C and NaH (471 mg, 
11.8 mmol, 6.0 eq, 60% dispersion in mineral oil) was added po rtionwise. The reaction mixture was stirred at 
this temperature for 10 minutes, warmed to RT, and stirred for a further 30 minutes. The reaction mixture was 
then once again cooled to 0 °C. BnBr (1.38 mL, 11.6 mmol, 5.9 eq) was added dropwise. The reaction 
mixture was stirred at 0 °C for 10 minutes, warmed to RT, and stirred for a further 15 hours. After quenching 
with H2O (8 mL), the aqueous phase was extracted with EtOAc (4 × 10 mL) and the combined organic layers 
were washed with H2O (10 mL), and brine (10 mL), then dried (MgSO4), filtered, and concentrated in vacuo. 
The residue obtained was purified by column chromatography over silica gel (Petroleum ether/EtOAc 9.5:0.5, 
9:1, 8.5:1.5, 8:2, 8:3) to give 12 (1.04 g, 80%) as a colourless solid: mp: 102–103 °C; TLC (Petroleum 
ether:EtOAc, 7:3 v/v): Rf = 0.66; 
1
H NMR (500 MHz; CDCl3): δ 7.36–7.23 (m, 25H, H-12 to H-16, H-19 to 
12
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H-23, H-26 to H-30, H-33 to H-37 and H-40 to H-44), 5.98 (dddd, 1H, J = 17.4, 10.3, 6.0, 6.0 Hz, H-8), 5.30 
(dddd, JXY = 17.4, 1.8, 1.7, 1.7 Hz, 1H, H-9), 5.18 (dddd, JXY = 10.3, 1.8, 1.4, 1.4 Hz, 1H, H-9’), 4.91 (d, JAB = 
10.6 Hz, 2H, H-10 and H-24), 4.87 (s, 2H, H-17), 4.82 (d, JAB = 10.6 Hz, 2H, H-10’ and H-24’), 4.68 (d, JAB = 
12.2 Hz, 2H, H-31 and H-38), 4.66 (d, JAB = 12.2 Hz, 2H, H-31’ and H-38’), 4.34 (ddd, JXY 6.0, 1.7, 1.4 Hz, 
2H, H-7 and H-7’), 4.03 (dd, J = 9.7, 9.4 Hz, 2H, H-4 and H-6), 3.97 (dd, J = 2.4, 2.4 Hz, 1H, H-2), 3.46 (dd, 
J = 9.4, 9.4 Hz, 1H, H-5), 3.33 (dd, J 9.7, 2.4 Hz, 2H, H-1 and H-3); 
13
C NMR (126 MHz; CDCl3): δ 139.00 
(C-11, C-25), 138.97 (C-18), 138.5 (C-32, C-39), 135.9 (C-8), 128.53, 128.49, 128.46, 128.2, 128.0, 127.8, 
127.6 (C-12 to C-16, C-19 to C-23, C-26 to C-30, C-33 to C-37 and C-40 to C-44), 117.0 (C-9), 83.8 (C-5), 
81.8 (C-4, C-6), 80.9 (C-1, C-3), 76.1 (C-17), 76.0 (C-10, C-24), 74.0 (C-2), 73.6 (C-7), 72.9 (C-31, C-38); IR 
(thin film): 3065 (w), 3029 (w), 2921 (w), 2874 (w), 1497 (w), 1454 (w), 1358 (m), 1215 (w), 1159 (w), 1130 
(m), 1090 (s), 1066 (s), 1039 (s), 1029 (s), 998 (m), 930 (w), 749 (m), 730 (s), 694 (s) cm
−1
; LRMS (m/z): 
[M+Na]
+ 
693.3; HRMS (m/z): [M+H]
+
 calcd. for C44H47O6, 671.33672; found 671.33641. These data are in 
good agreement with the literature values
10
. 
Synthetic protocol and characterisation data for 1,3,4,5,6-penta-O-benzyl-myo-inositol (13) 
(13) 
To a solution of 12 (820 mg, 1.22 mmol, 1.0 eq) in anhydrous MeOH/CH2CH2 (2.5:1.0 v/v, 8.8 mL) 
was added PdCl2 (24 mg, 0.133 mol, 0.11 eq). The reaction mixture was stirred at RT for 18 hours, then 
diluted with CH2Cl2 (5 mL), filtered through a pad of Celite
®
 and washed with CH2Cl2 (3 × 5 mL). The filtrate 
was concentrated in vacuo, and the residue obtained was purified by column chromatography over silica gel 
(Petroleum ether/EtOAc 9:1, 8:2, 7:3), to give 13 (739 mg, 96%) as a colourless solid: mp: 129–130 °C (lit.11 
128–129 °C; lit.12 128–130 °C); TLC (Petroleum ether:EtOAc, 7:3 v/v): Rf = 0.43; 
1
H NMR (400 MHz; 
CDCl3): δ 7.37–7.24 (m, 25H, H-9 to H-13, H-16 to H-20, H-23 to H-27, H-30 to H-34 and H-37 to H-41), 
12
3 4 5
6
HO38
O36
O
35 O
29
O
30
O
28
16
15
14 17
18
19
202137
40
34
41
39
3132
33
137
12
8
9
10
11
22
23
24
25
26
27
 11 
4.93–4.82 (m, 6H, H-7, H-14 and H-21), 4.73 (d, JAB = 12.3 Hz, 2H, H-28 and H-35), 4.70 (d, JAB = 12.3 Hz, 
2H, H-28’ and H-35’), 4.22 (dd, J = 2.6, 2.6 Hz, 1H, H-2), 4.00 (dd, J = 9.5, 9.5 Hz, 2H, H-4 and H-6), 3.46 
(dd, J = 9.5, 9.5 Hz, 1H, H-5), 3.39 (dd, J = 9.5, 2.6 Hz, 2H, H-1 and H-3), 2.45 (br s, 1H, C(2)OH); 
13
C NMR 
(101 MHz; CDCl3): δ 138.91 (C-8, C-22), 138.85 (C-15), 138.1 (C-29, C-36), 128.6, 128.5, 128.1, 128.02, 
127.98, 127.71, 127.68 (C-9 to C-13, C-16 to C-20, C-23 to C-27, C-30 to C-34 and C-37 to C-41), 83.3 
(C-5), 81.4 (C-4, C-6), 80.0 (C-1, C-3), 76.1 (C-7, C-14, C-21), 72.9 (C-28, C-35), 67.7 (C-2); IR (thin film): 
3449 (O-H) (br), 3065 (w), 3032 (w), 2882 (w), 1497 (w), 1454 (m), 1358 (m), 1134 (m), 1086 (m), 1064 (s), 
1030 (s), 914 (w), 753 (s), 726 (s), 695 (s) cm
−1
; LRMS (m/z): [M+Na]
+
 653.3; HRMS (m/z): [M+H]
+
 calcd. 
for C41H43O6, 631.30542; found 631.30512. The data are in good agreement with the literature values
11–13
. 
Synthetic protocol and characterisation data for 2,3,4,5,6-penta-O-benzyl-1-azido-1-deoxy-scyllo-
inositol (14) 
(14) 
A solution of 13 (100 mg, 0.159 mmol, 1.0 eq) in anhydrous pyridine (1.4 mL) was cooled to 0 °C. 
Methanesulfonyl chloride (288 µL, 3.73 mmol, 23.5 eq) was added  dropwise. The cloudy solution obtained 
was gradually warmed to RT and was stirred for a further 24 hours. The reaction was then quenched by the 
addition of H2O (1 mL) and diluted with CH2Cl2 (2 mL). The aqueous phase was extracted with CH2Cl2 (3 × 2 
mL) and the combined organic layers were washed with H2O (2 × 1 mL), and brine (2 × 1 mL), then dried 
(Na2SO4), filtered, and concentrated in vacuo. Without any further purification the presumed crude mesyl 
inositol intermediate obtained was dissolved in anhydrous DMF (1.4 mL). NaN3 (75 mg, 1.16 mmol, 7.3 eq) 
was added in one portion and the reaction mixture was stirred at 90 °C for 15 hours. After cooling to RT, H2O 
(2 mL) was added. The aqueous phase was extracted with CH2Cl2 (3 × 2 mL), and the combined organic 
layers were washed with H2O (2 × 1 mL), a saturated aqueous solution of NaHCO3 (1 mL), and brine (2 × 1 
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mL), then dried (MgSO4), filtered, and concentrated in vacuo. Purification by column chromatography over 
silica gel (Petroleum ether/EtOAc 9.5:0.5, 9:1, 8:2) yielded 14 (91 mg, 88%) as a yellow solid: mp: 96–97 °C 
(lit.
13
 95–96 °C); TLC (Petroleum ether:EtOAc, 4:1 v/v): Rf = 0.65; 
1
H NMR (500 MHz; CDCl3): δ 7.41–7.25 
(m, 25H, H-9 to H-13, H-16 to H-20, H-23 to H-27, H-30 to H-34 and H-37 to H-41), 4.93–4.84 (m, 10H, 
H-7, H-14, H-21, H-28 and H-35), 3.62–3.52 (m, 10H, H-3, H-4 and H-5), 3.49 (dd, J = 10.1, 10.1 Hz, 1H, 
H-1), 3.36 (dd, J = 9.0, 9.0 Hz, 2H, H-2 and H-6); LRMS (m/z): 678.3 ([M+Na]
+
; HRMS (m/z): [M+Na]
+
 
calcd. for C41H41O5N3Na, 678.29384; found 678.29340. The data are in good agreement with the literature 
values
13,14
. 
Synthetic protocol and characterisation data for 2,3,4,5,6-tetra-O-benzyl-scyllo-inosamine (15) 
(15) 
To a solution of 14 (2.00 g, 3.05 mmol, 1.0 eq) in THF (49 mL) was added PPh3 (1.60 g, 6.10 mmol, 
2.0 eq) and H2O (2.1 mL). The solution was stirred at 40 °C for 30 hou rs, then cooled to RT. The solvents 
were concentrated in vacuo and the residue obtained was redissolved in CH2Cl2 (10 mL) and H2O (5 mL) was 
added. The aqueous layer was extracted with CH2Cl2 (4 × 10 mL) and the combined organic layers were 
washed with H2O (10 mL), and brine (10 mL), then dried (Na2SO4), filtered, and concentrated in vacuo. 
Purification by column chromatography over silica gel (Petroleum ether/EtOAc/Et3N 9.5:0.45:0.05, 
9:0.95:0.05, 8:1.95:0.05, 7:2.95:0.05, 6:3.95:0.05, 5:4.95:0.05) gave 15 (1.40 g, 73%) as a colourless glassy 
solid: mp: 122–123 °C; TLC (Petroleum ether:EtOAc, 5:5 v/v): Rf = 0.59; 
1
H NMR (500 MHz; CDCl3): δ 
7.37–7.27 (m, 25H, H-9 to H-13, H-16 to H-20, H-23 to H-27, H-30 to H-34 and H-37 to H-41), 4.99 (d, JAB = 
10.9 Hz, 2H, H-28 and H-35), 4.93 (d, JAB = 10.8 Hz, 2H, H-7 and H-21), 4.91 (s, 2H, H-14), 4.86 (d, JAB = 
10.8 Hz, 2H, H-7’ and H-21’), 4.70 (d, JAB = 10.9 Hz, 2H, H-28’ and H-35’), 3.65–3.59 (m, 3H, H-3, H-4 and 
H-5), 3.40–3.31 (m, 2H, H-2 and H-6), 2.94 (dd, J = 9.9, 9.9 Hz, 1H, H-1); 13C NMR (126 MHz; CDCl3): δ 
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138.55 (C-15), 138.51, 138.48 (C-8, C-22, C-29, C-36), 128.7, 128.61 (C-10, C-12, C-24, C-26, C-31, C-33, 
C-38, C-40), 128.58 (C-17, C-19), 128.04, 128.02, 127.97, 127.94, 127.85, 127.82 (C-9, C-11, C-13, C-16, C-
18, C-20, C-23, C-25, C-27, C-30, C-32, C-34, C-37, C-39, C-41), 84.5 (C-2, C-6), 83.7 (C-4), 83.1 (C-3, 
C-5), 76.2 (C-14), 76.0, 75.9 (C-7, C-21, C-28, C-35), 55.5 (C-1); IR (thin film): 3067 (N-H) (w), 3030 (N-H) 
(w), 2908 (w), 2870 (w), 1574 (w), 1496 (w), 1454 (w), 1351 (m), 1215 (w), 1151 (w), 1126 (m), 1094 (m), 
1062 (s), 1040 (s), 1026 (s), 1011 (s), 906 (w), 830 (w), 751 (s), 694 (s), 661 (m), 624 (m) cm
−1
; LRMS (m/z): 
[M+H]
+
 630.3; HRMS (m/z): [M+H]
+
 calcd. for C41H44NO5, 630.32140; found 630.32066; RP-HPLC 
(Method 1) tR = 11.46 min, 95.25%. 
 
Synthetic protocol and characterisation data for scyllo-inosamine hydrochloride (1) 
(1) 
To a solution of the protected amine 15 (304 mg, 0.483 mmol, 1.0 eq) in CH2Cl2/MeOH/H2O (3:2:1 
v/v/v, 7.2 mL) was added 10% Pd/C (82 mg, 0.0773 mmol, 0.16 eq) and molecular biology grade concentrated 
HCl (200 µL) under N2(g). The flask was purged with 3 balloons of H2(g), and the suspension was stirred at RT 
under H2(g) for 24 hours. The reaction mixture was filtered through a glass microfiber filter and washed with 
MeOH/H2O (4:1 v/v, 20 mL). The filtrate was partially concentrated in vacuo, then lyophilised. The colourless 
solid obtained was then dissolved in the minimal amount of H2O (0.3 mL) and loaded onto a pre-washed 
DOWEX
®
 50WX8 cation exchange column (∼3 mL of resin). The column was eluted with H2O (10 mL), then 
0.1 M HCl (10 mL) and 0.2 M HCl (5 mL). The fractions were combined and lyophilised to give the 
hydrochloride salt 1 (83 mg, 80%) as a colourless solid: decomp. 290–291 °C (lit.14 299 °C); 1H NMR 
(400 MHz; D2O): δ 3.49 (dd, 2H, J = 10.5, 9.0 Hz, H-2 and H-6), 3.42 (dd, J = 9.2, 9.0 Hz, 2H, H-3 and H-5), 
3.35–3.29 (m, 1H, H-4), 3.04 (dd, J = 10.5, 10.5 Hz, 1H, H-1); 13C NMR (126 MHz; D2O): δ 74.2 (C-3, C-5), 
73.1 (C-4), 70.1 (C-2, C-6), 55.7 (C-1); LRMS (m/z): [M+H]
+
 180.1; GC-MS (derivatised with TMSI) 
tR = 16.81 min, 100%. The data are in good agreement with the literature values
13,14
.  
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Synthetic protocol and characterisation data for (±)-4-O-(4-methoxybenzyl)-6-O-methyl-myo-inositol 
1,3,5-orthoformate i.e. (±)-(24) 
(±)-(24) 
To a solution of 8 (19.7 g, 104 mmol, 1.0 eq) in anhydrous DMF (150 mL) was added NaH (4.24 g, 
106 mmol, 1.02 eq, 60% dispersion in mi neral oil) portionwise over 10 minutes. The solution was stirred at 
RT for 30 minutes, then MeI (6.73 mL, 108 mmol, 1.04 eq) was added dropwise. After 16 hours stirring at 
RT, NaH (4.24 g, 106 mmol, 1.02 eq, 60% dispersion in mineral oil) was added portionwise and the reaction 
mixture was stirred for 1 hour. PMBCl (14.9 mL, 108 mmol, 1.04 eq) was then added dropwise over 
10 minutes, and the solution was stirred at RT for 16 hours. The reaction was quenched by addition of H2O 
(2 mL) and diluted in CH2Cl2 (20 mL). The aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The 
combined organic phases were washed with H2O (2 × 10 mL), brine (2 × 10 mL), and an aqueous solution of 
LiCl (10% w/v, 2 × 10 mL), then dried (MgSO4), filtered, and concentrated in vacuo. The residue obtained 
was purified twice by column chromatography over silica gel (Petroleum ether/EtOAc 8:2, 7:3, 6:4, 5:5) to 
give (±)-24 (1.56 g, 46%) as a yellow oil. This compound could not be purified further due to contamination 
by other regioisomers, which could only be separated in subsequent steps: TLC (Petroleum ether:EtOAc, 1:1 
v/v): Rf = 0.27; 
1
H NMR (400 MHz; CDCl3): δ 7.28–7.22 (m, 2H, H-11 and H-15), 6.91–6.85 (m, 2H, H-12 
and H-14), 5.45 (s, 1H, H-7), 4.59 (d, JAB = 11.5 Hz, 1H, H-9), 4.51 (d, JAB = 11.5 Hz, 1H, H-9’), 4.42–4.38 
(m, 1H, H-5), 4.32–4.27 (m, 1H, H-4), 4.25–4.21 (m, 1H, H-1), 4.18–4.10 (m, 2H, H-6 and H-3), 4.09–4.06 
(m, 1H, H-2), 3.80 (s, 3H, H-16), 3.44 (s, 3H, H-8), 3.09–2.97 (m, 1H, C(2)OH); 13C NMR (101 MHz; 
CDCl3): δ 159.6 (C-13), 129.8 (C-10), 129.4 (C-11, C-15), 114.1 (C-12, C-14), 103.5 (C-7), 76.0 (C-6), 73.3 
(C-4), 73.1 (C-3), 72.7 (C-1), 71.5 (C-9), 67.7 (C-5), 61.5 (C-2), 57.7 (C-8), 55.4 (C-16); IR (thin film): 3476 
(O-H) (br), 2980 (w), 2884 (w), 1734 (m), 1612 (w), 1514 (m), 1373 (w), 1302 (w), 1242 (s), 1144 (s) cm
−1
; 
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LRMS (m/z): [M+Na]
+
 347.1; HRMS (m/z): [M+Na]
+
 calcd. for C17H24O6Na, 347.1107; found 347.10932; 
RP-HPLC (Method 1) tR = 10.62 min, 85.85%.  
Synthetic protocol and characterisation data for (±)-2-O-allyl-4-O-(4-methoxybenzyl)-6-O-methyl-myo-
inositol 1,3,5-orthoformate i.e. (±)-(16) 
(±)-(16) 
A solution of (±)-24 (14.8 g, 45.6 mmol, 1.0 eq) in anhydrous DMF (250 mL) was cooled to 0 °C. 
NaH (4.56 g, 114 mmol, 2.5 eq, 60% dispersion in mineral oil) was added portionwise over 10 minutes. The 
reaction mixture was warmed to RT and stirred f or 2 hours. Allyl bromide (7.90 mL, 91.3 mmol, 2.0 eq) was 
subsequently added dropwise at 0 °C. The solution was warmed to RT and stirred for a further 17 hours. The 
reaction was quenched with H2O (60 mL) and the aqueous layer was extracted with EtOAc (3 × 40 mL). The 
combined organic layers were washed with H2O (2 × 30 mL), and brine (2 × 30 mL), then dried (MgSO4), 
filtered, and concentrated in vacuo. Purification twice by column chromatography over silica gel (Petroleum 
ether/EtOAc 9:1, 8:2, 7:3, 6:4, 5:5) gave (±)-16 (9.08 g, 55%) as a colourless oil. 
1
H NMR analysis indicated 
that this compound was contaminated with ~3% of regioisomers: TLC (Petroleum ether/EtOAc, 5:5 v/v): Rf = 
0.67; 
1
H NMR (400 MHz; CDCl3): δ 7.28–7.23 (m, 2H, H-11 and H-15), 6.92–6.86 (m, 2H, H-12 and H-14), 
5.98 (dddd, JXY = 17.1, 10.7, 5.6, 5.4 Hz, 1H, H-18), 5.50 (s, 1H, H-7), 5.36–5.28 (m, 1H, H-19), 5.24–5.18 
(m, 1H, H-19’), 4.61 (d, JAB = 11.7 Hz, 1H, H-9), 4.50 (d, JAB = 11.7 Hz, 1H, H-9’), 4.41–4.37 (m, 1H, H-5), 
4.36–4.31 (m, 1H, H-1), 4.31–4.27 (m, 1H, H-4), 4.24–4.19 (m, 1H, H-3), 4.17–4.10 (m, 3H, H-6 and H-17), 
3.88–3.85 (m, 1H, H-2), 3.81 (s, 3H, H-16), 3.44 (s, 3H, H-8); 13C NMR (101 MHz; CDCl3): δ 159.6 (C-13), 
134.8 (C-18), 129.9 (C-10), 129.4 (C-11, C-15), 117.8 (C-19), 114.1 (C-12, C-14), 103.4 (C-7), 76.2 (C-6), 
73.8 (C-4), 71.7 (C-9), 70.8 (C-17), 70.7 (C-3), 70.4 (C-1), 68.0 (C-5), 67.6 (C-2), 57.6 (C-8), 55.4 (C-16); IR 
(thin film): 3564 (w), 2995 (w), 2916 (m), 2837 (w), 1612 (m), 1514 (s), 1464 (w), 1302 (m), 1250 (s), 1175 
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(s), 1138 (s) cm
−1
; LRMS (m/z): [M+Na]
+
 387.2; HRMS (m/z): [M+H]
+
 calcd. for C19H25O7, 365.16003; 
found 365.15893; RP-HPLC (Method 1) tR = 13.45 min, 97.11%.  
Synthetic protocol and characterisation data for (±)-2-O-allyl-4-O-(4-methoxybenzyl)-6-O-methyl-myo-
inositol-1,3-O-methylene i.e. (±)-(17) 
(±)-(17) 
To a solution of (±)-16 (10.3 g, 28.2 mmol, 1.0 eq) in anhydrous CH2Cl2 (140 mL) at 0 °C was added 
DIBAL-H (141 mL, 141 mmol, 5.0 eq, 1.0 M in hexane) dropwise over 10 minutes. After stirring at 0 °C for 
10 minutes, the solution was warmed to RT and stirred for 24 hours. The reaction was then quenched by slow 
addition of a 1.0 M aqueous solution of Rochelle’s salt (20 mL) and a saturated aqueous solution of NH4Cl 
(20 mL) at 0 °C. After 30 minutes, the solution was warmed to RT, stirred for a further hour and then diluted 
in CH2Cl2 (20 mL). The aqueous phase was extracted with CH2Cl2 (3 × 20 mL), and the combined organic 
layers were washed with brine (15 mL), then dried (MgSO4), filtered, and concentrated in vacuo. Purification 
by column chromatography over silica gel (Petroleum ether/EtOAc 7:3) afforded a yellowish oil which was 
cooled to −20 °C for 48 hours to give a colourless solid which was crystallised from Et2O to yield (±)-17 (3.05 
g, 90%) as a colourless crystalline solid: mp: 63–65 °C; TLC (Petroleum ether:EtOAc, 1:1 v/v): Rf = 0.42; 
1
H NMR (400 MHz; CDCl3): δ 7.30–7.23 (m, 2H, H-11 and H-15), 6.92–6.84 (m, 2H, H-12 and H-14), 5.94 
(dddd, J = 17.1, 10.5, 5.6, 5.4 Hz, 1H, H-18), 5.47 (d, JAB = 5.0 Hz, 1H, H-7), 5.35–5.26 (m, 1H, H-19), 5.24–
5.17 (m, 1H, H-19’), 4.66 (d, JAB = 5.0 Hz, 1H, H-7’), 4.62 (d, JAB = 11.8 Hz, 1H, H-9), 4.55 (d, JAB = 11.8 
Hz, 1H, H-9’), 4.41–4.37 (m, 1H, H-1), 4.33–4.29 (m, 1H, H-3), 4.12–4.07 (m, 2H, H-17), 4.06–4.03 (m, 1H, 
H-2), 3.97–3.93 (m, 1H, H-4), 3.88–3.83 (m, 1H, H-5), 3.81 (s, 3H, H-16), 3.79–3.76 (m, 1H, H-6), 3.46 (s, 
3H, H-8), 2.91 (br s, 1H, C(5)OH); 
13
C NMR (101 MHz; CDCl3): δ 159.5 (C-13) 134.4 (C-18), 130.1 (C-10), 
129.5 (C-11, C-15), 117.4 (C-19), 114.1 (C-12, C-14), 85.1 (C-7), 83.7 (C-6), 80.8 (C-4), 72.8 (C-3), 72.3 (C-
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1), 72.0 (C-9), 70.4 (C-2), 69.83 (C-17), 69.77 (C-5), 58.3 (C-8), 55.4 (C-16); IR (thin film): 3545 (O-H) (br), 
2933 (w), 2920 (w), 1611 (w), 1514 (m), 1408 (w), 1250 (m), 1184 (m), 1134 (s), 1094 (s), 1060 (s), 1028 (s) 
cm
−1
; LRMS (m/z): [M+Na]
+
 389.2; HRMS (m/z): [M+Na]
+
 calcd. for C19H26O7Na, 389.15762; found 
389.15637; RP-HPLC (Method 1) tR = 11.62 min, 96.99%. 
Synthetic protocol and characterisation data for (±)-2-O-allyl-5-O-benzyl-4-O-(4-methoxybenzyl)-6-O-
methyl-myo-inositol-1,3-O-methylene i.e. (±)-(18) 
(±)-(18) 
A solution of (±)-17 (5.19 g, 14.2 mmol, 1.0 eq) in anhydrous DMF (40 mL) was cooled to 0 °C. 
Imidazole (675 mg, 9.91 mmol, 0.70 eq) was added to the solution, followed by NaH (1.70 g, 42.5 mmol, 3.0 
eq, 60% dispersion in mineral oil). The reaction mixture was stirred at 0 °C for 10 minutes, warmed to RT, 
and stirred for a further 45 minutes. BnBr (5.05 mL, 42.5 mmol, 3.0 eq) was subsequently added dropwise at 
0 °C. The reaction mixture was stirred for 25 minutes, warmed to RT, and stirred for 20 hours. The reaction 
was quenched with H2O (25 ml) and diluted in EtOAc (25 mL). The aqueous phase was extracted with EtOAc 
(5 × 20 mL), and the combined organic layers were washed with brine (2 × 20 mL), H2O (2 × 20 ml), and an 
aqueous solution of LiCl (10% w/v, 20 mL). The organic phase was then dried (MgSO4), filtered, and 
concentrated in vacuo. Purification by column chromatography over silica gel (Petroleum ether/EtOAc 9:1, 
8.5:1.5, 8.2) afforded (±)-18 (6.03 g, 93%) as a thick colourless oil: TLC (Petroleum ether:EtOAc, 5:5 v/v): Rf 
= 0.75; 
1
H NMR (400 MHz; CDCl3): δ 7.29–7.14 (m, 7H, H-11, H-15 and H-22 to H-26), 6.82–6.76 (m, 2H, 
H-12 and H-14), 5.90 (dddd, J = 17.2, 10.5, 5.9, 5.5 Hz, 1H, H-18), 5.30–5.21 (m, 1H, H-19), 5.18–5.11 (m, 
1H, H-19’), 5.05 (d, JAB = 5.6 Hz, 1H, H-7), 4.78 (d, JAB = 5.6 Hz, 1H, H-7’), 4.62 (s, 2H, H-20), 4.52 (d, 
JAB = 11.4 Hz, 1H, H-9), 4.52 (d, JAB = 11.4 Hz, 1H, H-9’), 4.16–4.12 (m, 1H, H-1), 4.11–4.03 (m, 3H, H-3 
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and H-17), 3.89–3.85 (m, 1H, H-4), 3.73 (s, 3H, H-16), 3.65–3.60 (m, 1H, H-6), 3.60–3.56 (m, 1H, H-2), 3.46 
(dd, J = 5.9, 5.9 Hz, 1H, H-5), 3.35 (s, 3H, H-8); 
13
C NMR (101 MHz; CDCl3): δ 159.6 (C-13), 138.6 (C-21), 
134.5 (C-18), 129.9 (C-10), 129.7 (C-11, C-15), 128.5 (C-23, C-25), 127.9 (C-22, C-26), 127.8 (C-24), 117.7 
(C-19), 114.0 (C-12, C-14), 85.6 (C-7), 84.8 (C-6), 81.8 (C-4), 80.8 (C-5), 73.6 (C-20), 72.3 (C-1), 71.8 (C-3), 
71.7 (C-9), 70.1 (C-2, C-17), 57.7 (C-8), 55.4 (C-16); IR (thin film): 2864 (w), 2836 (w), 1612 (w), 1514 (m), 
1455 (w), 1366 (w), 1248 (m), 1176 (m), 1084 (s), 1029 (s), 1012 (s), 821 (m), 733 (s), 698 (s) cm
−1
; LRMS 
(m/z): [M+Na]
+
 479.2; HRMS (m/z): [M+Na]
+
 calcd. for C26H32O7Na, 479.20402; found 479.20308; RP-
HPLC (Method 1) tR = 14.56 min, 94.32%. 
Synthetic protocol and characterisation data for (±)-2-O-allyl-5-O-benzyl-6-O-methyl-myo-inositol i.e. 
(±)-(19) 
(±)-(19) 
To a solution of (±)-18 (832 mg, 1.82 mmol, 1.0 eq) in MeOH (10 mL) at 0 °C was added 
concentrated HCl (1.30 mL). The solution was warmed to RT and subsequently heated under reflux for 
2 hours. After cooling to RT, the reaction was quenched with a saturated aqueous solution of NaHCO3 until 
the pH reached 7. The volatile components were concentrated in vacuo and the residue obtained was purified 
by column chromatography over silica gel (Petroleum ether/EtOAc 3:7, 2:8, 1:9). The colourless solid 
obtained was then crystallised from EtOAc to give (±)-19 (518 mg, 88%) as a colourless crystalline solid: 
mp: 141–143 °C; TLC (Petroleum ether:EtOAc, 1:1 v/v): Rf = 0.32;  
1
H NMR (400 MHz; CDCl3): δ 4.41–7.28 
(m, 5H, H-13 to H-17), 5.93 (dddd, J = 17.2, 10.4, 5.6, 5.6 Hz, 1H, H-9), 5.30 (dddd, JXY = 17.2, 1.9, 1.7, 1.5 
Hz, 1H, H-10), 5.20 (dddd, JXY = 10.4, 1.9, 1.6, 1.4 Hz, 1H, H-10’), 4.90 (d, JAB = 11.4 Hz, 1H, H-11), 4.78 
(d, JAB = 11.4 Hz, 1H, H-11’), 4.36 (dddd, JXY = 12.9, 5.6, 1.7, 1.6 Hz, 1H, H-8), 4.31 (dddd, JXY = 12.9, 5.6, 
1.5, 1.4 Hz, 1H, H-8’), 3.92 (dd, J = 2.6, 2.6 Hz, 1H, H-2), 3.82–3.75 (m, H-41H,), 3.66 (s, 3H, H-7), 3.54–
3.48 (m, 1H, H-1 or H-3), 3.48–3.40 (m, 2H, H-1 or H-3 and H-6), 3.23 (dd, J = 9.0, 9.0 Hz, 1H, H-5), 2.45 
(d, J = 1.6 Hz, 1H, C(4)OH), 2.42 (d, J = 5.5 Hz, 1H, C(1)OH or C(3)OH), 2.38 (d, J = 6.5 Hz, 1H, C(1)OH or 
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C(3)OH); 
13
C NMR (101 MHz; CDCl3): δ 138.7 (C-12), 135.0 (C-9), 128.7 (C-14, C-16), 128.1 (C-13, C-17), 
128.0 (C-15), 117.1 (C-10), 83.9 (C-6), 83.0 (C-5), 78.7 (C-2), 75.1 (C-11), 74.4 (C-8), 74.1 (C-4), 72.9 (C-1 
or C-3), 72.6 (C-1 or C-3), 61.4 (C-7); IR (thin film): 3360 (O-H) (br), 2918 (w), 1498 (w), 1362 (w), 1192 
(m), 1156 (s), 1053 (s), 1033 (s), 923 (m), 913 (m), 733 (s), 695 (s) cm
−1
; LRMS (m/z): [M+Na]
+
 347.1; 
HRMS (m/z): [M+Na]
+
 calcd. for C17H24O6Na, 347.14651; found 347.14600; RP-HPLC (Method 1) tR = 9.09 
min, 98.22%; Chiral HPLC (Heptane/IPA 90:10, 0.8 mL.min
−1
, 254 nm) tR = 19.59 min, 50.49% (+)-1L-19, 
tR = 22.39 min, 49.51% (−)-1D-19. 
Synthetic protocol and characterisation data for (+)-1D-1-O-((S)-α-methoxyphenylacetoxy)-2-O-allyl-
3,4-O-(L-1,7,7-trimethyl[2.2.1]bicyclohept-2-ylidene)-5-O-benzyl-6-O-methyl-myo-inositol i.e. (+)-1D-
(25) 
(+)-1D-(25) 
To a solution of (±)-19 (2.00 g, 6.17 mmol, 1.0 eq) in anhydrous CH2Cl2 (39 mL) were added 1-(S)-
(−)-camphor dimethylacetal (3.67 g, 18.5 mmol, 3.0 eq) and PTSA·H2O (59 mg, 0.308 mmol, 0.050 eq). The 
solution was heated under reflux for 24 hours, allowed to cool to RT and quenched with Et3N (43 μL, 
0.308 mmol, 0.050 eq). The solvent was removed in vacuo. The residue obtained, containing a mixture the 
four diastereoisomers 20a–d, was then purified  and resolved by column chromatography over silica gel 
(Petroleum ether/EtOAc 9.7:0.3, 9.6:0.4, 9.5:0.5, 9.4:0.6, 9.3:0.7, 9.2:0.8, 9.1:0.9, 9:1, 8.8:1.2, 8.5:1.5, 8:2, 
7.5:2.5, 7:3, 6.5:3.5, 6:4) to give a mixture of diastereoisomers of 20b–d (1.90 g, 67%) and (−)-1D-20a 
(466 mg, 16%) as colourless oils.  
Deprotection of a small sample of (−)-1D-20a, with acetyl chloride (2.48 mmol, 0.60 eq) in 
MeOH/CH2Cl2 (1.0:1.8 v/v) for 21 hours, as described below, and analysis of the triol (−)-19 obtained by 
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chiral HPLC revealed that this material was only partially resolved: Chiral HPLC (Heptane/IPA 90:10, 
0.8 mL.min
−1
, 254 nm) tR = 19.74 min, 72.40% (+)-1L-19, tR = 22.60 min, 27.60% (−)-1D-19, 45% e.e. 
Intermediate (−)-1D-20a was thus further resolved, and its e.e. was simultaneous determined, using 
α-methoxyphenylacetic acid: To a solution of (−)-1D-20a (15 mg, 0.0327 mmol, 1.0 eq) in CH2Cl2 (0.30 mL) 
were added (S)-(+)-α-methoxyphenylacetic acid (14 mg, 0.0818 mmol, 2.5 eq), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (14 mg, 0.0883 mmol, 2.7 eq) and 4-DMAP (2 mg, 0.0164 mmol, 
0.50 eq). After 42 hours stirring at RT, the reaction mixture was diluted with CH2Cl2 (3 mL), and the organic 
layer was washed with a saturated aqueous solution of NaHCO3 (2 × 5 mL), and brine (5 mL), then dried 
(MgSO4), filtered, and concentrated in vacuo. Purification by column chromatography over silica gel 
(Petroleum ether/EtOAc 9:1, 8:2) yielded (+)-1D-25 (18 mg, 90%) as a colourless oil: TLC (Petroleum 
ether:EtOAc, 4:1 v/v): Rf = 0.43; [α]D
25 = +27.2 (c 1.0 in CHCl3); 
1
H NMR (500 MHz; CDCl3): δ 7.51–7.45 
(m, 2H, H-29 and H-33), 7.40–7.24 (m, 8H, H-13 to H-17 and H-30 to H-32), 5.46 (dddd, J = 17.4, 10.6, 5.5, 
5.4 Hz, 1H, H-9), 5.08–5.02 (m, 1H, H-10), 5.01–4.95 (m, 1H, H-10’), 4.89 (d, JAB = 11.8 Hz, 1H, H-11), 4.83 
(dd, J = 9.9, 2.8 Hz, 1H, H-1), 4.82 (s, 1H, H-26), 4.72 (d, JAB = 11.8 Hz, 1H, H-11’), 3.97–3.85 (m, 3H, H-8, 
H-2 and H-4), 3.63–3.55 (m, 2H, H-8’ and H-6), 3.52 (s, 3H, H-7), 3.54–4.48 (m, 1H, H-5), 3.44 (s, 3H, 
H-27), 3.22 (dd, J = 9.8 Hz, 1H, 1.0, H-3), 2.11 (dt, J = 13.3, 3.5 Hz, 1H, Heq-23), 1.84–1.75 (m, 1H, Heq-20), 
1.74–1.64 (m, 2H, H-22 and Heq-21), 1.40 (d, J = 13.3 Hz, 1H, Hax-23), 1.32 (td, J = 12.2, 4.2 Hz, 1H, Hax-20), 
1.20–1.11 (m, 1H, Hax-21), 1.03 (s, 3H, C(24)CH3), 0.84 (s, 3H, C(19)CH3 or C(24)CH3), 0.82 (s, 3H, 
C(19)CH3 or C(24)CH3); 
13
C NMR (126 MHz; CDCl3): δ 170.2 (C-25), 138.8 (C-12), 136.2 (C-28), 134.6 
(C-9), 128.9, 128.8, 128.4, 127.9, 127.6, 127.4 (C-13 to C-17 and C-29 to C-33), 120.8 (C-18), 116.8 (C-10), 
82.6 (C-26), 81.9 (C-6), 80.4 (C-5), 77.2 (C-4), 76.0 (C-3), 75.0 (C-1), 72.9 (C-8), 72.6 (C-11), 71.9 (C-2), 
61.5 (C-7), 57.6 (C-27), 53.0 (C-19), 48.4 (C-24), 46.2 (C-23), 45.0 (C-22), 28.9 (C-20), 26.7 (C-21), 20.4 
(C(24)CH3), 20.3 (C(24)CH3), 9.7 (C(19)CH3); IR (thin film): 2975 (m), 2932 (m), 2871 (m), 1754 (C=O) 
(m), 1496 (w), 1454 (m), 1371 (w), 1349 (w), 1310 (w), 1262 (w), 1202 (m), 1165 (m), 1153 (m), 1115 (s), 
1089 (s), 1067 (s), 1046 (m), 1028 (m), 1016 (m), 926 (m), 844 (w), 823 (w), 736 (m), 697 (s) cm
−1
; LRMS 
(m/z): [M+H]
+
 607.3; HRMS (m/z): [M+H]
+
 calcd. for C36H47O8, 607.32654; found 607.32603. 
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Synthetic protocols and characterisation data for (−)-1D-1-O-((R)-α-methoxyphenylacetoxy)-2-O-allyl-
3,4-O-(L-1,7,7-trimethyl[2.2.1]bicyclohept-2-ylidene)-5-O-benzyl-6-O-methyl-myo-inositol i.e. (−)-1D-
(25) 
(-)-1D-(25) 
The partially resolved intermediate (−)-1D-20a obtained as described above, was further resolved, and 
its e.e. determined, using α-methoxyphenylacetic acid: To a solution of (−)-1D-20a (15 mg, 0.0327 mmol, 
1.0 eq) in CH2Cl2 (0.30 mL) were added (R)-(−)-α-methoxy phenylacetic acid (14 mg, 0.0818 mmol, 2.5 eq), 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (14 mg, 0.0883 mmol, 2.7 eq) and 4-DMAP (2 mg, 
0.0164 mmol, 0.50 eq). After 42 hours stirring at RT, the reaction mixture was diluted with CH2Cl2 (3 mL), 
and the organic layer was washed with a saturated aqueous solution of NaHCO3 (2 × 5 mL), and brine (5 mL), 
then dried (MgSO4), filtered, and concentrated in vacuo. Purification by column chromatography over silica 
gel (Petroleum ether/EtOAc 9:1, 8:2) yielded (−)-1D-25 (7 mg, 57%) as a colourless oil: TLC (Petroleum 
ether:EtOAc, 4:1, v/v): Rf = 0.43; [α]D
25 = −29.6 (c 0.56, CHCl3); 
1
H NMR (400 MHz; CDCl3): δ 7.50–7.45 
(m, 2H, H-29 and H-33), 7.40–7.23 (m, 8H, H-13 to H-17 and H-30 to H-32), 5.80 (dddd, J = 17.4, 10.6, 5.5, 
5.4 Hz, 1H, H-9), 5.32–5.23 (m, 1H, H-10), 5.19–5.12 (m, 1H, H-10’), 4.86 (d, JAB = 11.8 Hz, 1H, H-11), 4.81 
(s, 1H, H-26), 4.75 (dd, J = 9.0, 3.3 Hz, 1H, H-1), 4.68 (d, JAB = 11.8 Hz, 1H, H-11’), 4.27–4.20 (m, 1H, H-8), 
4.20–4.16 (m, 1H, H-2), 4.04–3.97 (m, 1H, H-8’), 3.98–3.91 (m, 1H, H-4), 3.48–3.44 (m, 2H, H-5 and H-6), 
3.43 (s, 3H, H-27), 3.25 (dd, J = 9.9, 1.0 Hz, 1H, H-3), 3.05 (s, 3H, H-7), 2.12 (dt, J = 13.3, 3.5 Hz, 1H, 
Heq-23), 1.89–1.78 (m, 1H, Heq-20), 1.77–1.64 (m, 2H, H-22 and Heq-21), 1.43 (d, J = 13.3 Hz, 1H, Hax-23), 
1.36 (td, J = 12.2, 4.2 Hz, 1H, Hax-20), 1.23–1.14 (m, 1H, Hax-21), 1.05 (s, 3H, C(24)CH3), 0.85 (s, 6H, 
C(19)CH3 and C(24)CH3); 
13
C NMR (101 MHz; CDCl3): δ 170.3 (C-25), 138.8 (C-12), 136.1 (C-28), 134.7 
(C-9), 129.0, 128.8, 128.4, 127.9, 127.7, 127.6 (C-13 to C-17 and C-29 to C-33), 120.8 (C-18), 116.9 (C-10), 
82.8 (C-26), 81.9 (C-6), 80.7 (C-5), 77.4 (C-4), 76.2 (C-3), 75.2 (C-1), 73.0 (C-8), 72.7 (C-11), 72.1 (C-2), 
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61.2 (C-7), 57.4 (C-27), 53.1 (C-19), 48.4 (C-24), 46.1 (C-23), 45.1 (C-22), 29.0 (C-20), 26.8 (C-21), 20.4 
(C(24)CH3), 20.3 (C(24)CH3), 9.76 (C(19)CH3); IR (thin film): 2930 (br), 2874 (w), 1753 (w), 1735 (C=O) 
(w), 1454 (w), 1261 (m), 1202 (m), 1167 (m), 1109 (s), 1088 (s), 1066 (s), 1028 (s), 1015 (s), 926 (w), 737 
(m), 697 (s) cm
−1
; LRMS (m/z): [M+H]
+
 607.3; HRMS (m/z): [M+Na]
+
 calcd. for C36H46O8Na, 629.30849; 
found 629.30679; NP-HPLC (Method 3) tR = 5.69 min, 100%. 
Synthetic protocol and characterisation data for (+)-1D-1-O-((S)-acetylmandelyl)-3,4-O-(L-1,7,7-
trimethylbicyclo[2.2.1]hept-2-ylidene)-5-O-benzyl-6-O-methyl-myo-inositol i.e. (+)-1D-(21) & (−)-1L-1-
O-((R)-acetylmandelyl)-2-O-allyl-3,4-O-(L-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylidene)-5-O-benzyl-6-O-
methyl-myo-inositol i.e. (−)-1L-(21) 
   (+)-1D-(21)      (−)-1L-(21) 
To a solution of (±)-19 (2.00 g, 6.17 mmol, 1.0 eq) in anhydrous CH2Cl2 (39 mL) were added 1-(S)-
(−)-camphor dimethylacetal (3.67 g, 18.5 mmol, 3.0 eq) and PTSA·H2O (59 mg, 0.308 mmol, 0.050 eq). The 
solution was heated under reflux for 24 hours, allowed to cool to RT and quenched with Et3N (43 μL, 
0.308 mmol, 0.050 eq). The solvent was r emoved in vacuo. The residue obtained, containing a mixture of 
four diastereoisomers, was then purified and resolved by column chromatography over silica gel (Petroleum 
ether/EtOAc 9.7:0.3, 9.6:0.4, 9.5:0.5, 9.4:0.6, 9.3:0.7, 9.2:0.8, 9.1:0.9, 9:1, 8.8:1.2, 8.5:1.5, 8:2, 7.5:2.5, 7:3, 
6.5:3.5, 6:4) to give a mixture of diastereoisomers of 20b–d (1.90 g, 67%) and partially resolved (−)-1D-20a 
(466 mg, 16%) as colourless oils. Intermediate (−)-1D-20a was then further resolved using (S)-(+)-O-
acetylmandelic acid as a chiral auxiliary: To a solution of (−)-1D-20a (450 mg, 0.981 mmol, 1.0 eq) in CH2Cl2 
(9.3 mL) were added (S)-(+)-O-acetylmandelic acid (381 mg, 1.96 mmol, 2.0 eq), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (508 mg, 2.65 mmol, 2.7 eq) and 4-DMAP (60 mg, 0.491 mmol, 0.5 eq). 
After 17 hours stirring at RT the yellow solution was diluted with CH2Cl2 (4 mL), and washed with a 
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saturated aqueous solution of NaHCO3 (2 × 10 mL). The aqueous layer was then back-extracted with CH2Cl2 
(2 × 10 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo. 
Purification and further resolution by column chromatography over silica gel (Petroleum ether/EtOAc 9.9:0.1, 
9.8:0.2, 9.7:0.3, 9.6:0.4, 9.5:0.5, 9:1, 8.5:1.5, 8:2) yielded (+)-1D-21 (458 mg, 74%) as an amorphous, 
colourless foam: TLC (Petroleum ether:EtOAc, 4:1 v/v): Rf = 0.43; [α]D
25 = +11.9 (c 2.0, CH3Cl); 
1
H NMR 
(400 MHz; CDCl3): δ 7.54–7.48 (m, 2H, H-30 and H-34), 7.44–7.26 (m, 8H, H-13 to H-17 and H-31 to H-33), 
5.96 (s, 1H, H-26), 5.49 (dddd, J = 17.2, 10.3, 5.5, 5.4 Hz, 1H, H-9), 5.10–5.03 (m, 1H, H-10), 5.01–4.95 (m, 
1H, H-10’), 4.89 (d, JAB = 12.0 Hz, 1H, H-11), 4.86 (dd, J = 9.2, 3.2 Hz, 1H, H-1), 4.73 (d, JAB = 12.0 Hz, 1H, 
H-11’), 3.98–3.87 (m, 3H, H-8, H-4 and H-2), 3.70–3.63 (m, 1H, H-8’), 3.60 (dd, J = 9.2, 9.2 Hz, 1H, H-6), 
3.57 (s, 3H, H-7), 3.50 (dd, J = 9.2, 8.6 Hz, 1H, H-5), 3.20 (dd, J = 9.8, 1.4 Hz, 1H, H-3), 2.19 (s, 3H, H-28), 
2.10 (dt, J = 13.6, 3.8 Hz, 1H, Heq-23), 1.82–1.74 (m, 1H, Heq-20), 1.74–1.63 (m, 2H, H-22 and Heq-21), 1.39 
(d, J = 13.6 Hz, 1H, Hax-23), 1.29 (td, J = 12.0, 4.3 Hz, 1H, Hax-20), 1.19–1.10 (m, 1H, Hax-21), 1.04 (s, 3H, 
C(19)CH3), 0.83 (s, 3H, C(24)CH3), 0.82 (s, 3H, C(24)CH3); 
13
C NMR (101 MHz; CDCl3): δ 170.3 (C-25), 
168.4 (C-27), 138.8 (C-12), 134.6 (C-9), 133.8 (C-29), 129.4, 128.9, 128.4, 127.9, 127.6 (C-13 to C-17 and C-
30 to C-34), 120.8 (C-18), 116.6 (C-10), 82.1 (C-6), 80.4 (C-5), 77.4 (C-4), 76.1 (C-3), 75.4 (C-1), 74.6 
(C-26), 72.9 (C-8), 72.7 (C-11), 72.0 (C-2), 61.7 (C-7), 53.1 (C-19), 48.4 (C-24), 46.2 (C-23), 45.1 (C-22), 
29.0 (C-20), 26.7 (C-21), 20.8 (C-28), 20.4 (C(24)CH3), 20.3 (C(19)CH3), 9.69 (C(24)CH3); IR (thin film): 
2934 (br), 2873 (w), 2360 (w), 1749 (C=O) (s), 1454 (w), 1373 (m), 1263 (m), 1229 (s), 1206 (s), 1166 (m), 
1110 (s), 1087 (s), 1064 (s), 1047 (s), 918 (m), 734 (s), 696 (s) cm
−1
; LRMS (m/z): [M+H]
+
 635.3; HRMS 
(m/z): [M+H]
+
 calcd. for C37H47O9, 635.32146; found 635.3209; NP-HPLC (Method 3) tR = 6.56 min, 
99.73%. 
Acetyl chloride (177 μL, 2.48 mmol, 0.60 eq) was added to a solution of the diastereoisomeric 
mixture 20b–d (1.90 g, 4.14 mmol, 1.0 eq) in MeOH/CH2Cl2 (1.0:1.8 v/v, 27 mL). After stirring at RT for 21 
hours, the reaction was quenched with Et3N (346 μL, 2.48 mmol, 0.60 eq) and the solvents were removed in 
vacuo. The off-white solid obtained was then crystallised from EtOAc to give triol (+)-19 (1.34 g, 94%) 
enriched in the opposite enantiomer.  
 24 
Similarly therefore, from enriched (+)-19 or racemic (±)-19 (1.14 g, 3.51 mmol, 1.0 eq), 1-(R)-(+)-
camphor dimethylacetal (3.48 g, 17.6 mmol, 5.0 eq) and PTSA·H2O (33 mg, 0.176 mmol, 0.050 eq) in 
CH2Cl2 (18 mL), (+)-1L-20c (175 mg, 11% from racemic (±)-19, 589 mg, 37% from enriched (+)-19) was 
obtained as a colourless oil. Reaction of (+)-1L-20c (170 mg, 0.371 mmol, 1.0 eq) with (R)-(−)-O-
acetylmandelic acid (144 mg, 0.741 mmol, 2.0 eq), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (192 mg, 
1.00 mmol, 2.7 eq) and 4-DMAP (23 mg, 0.185 mmol, 0.50 eq) yielded (−)-1L-21 (191 mg, 74–81%) as a 
colourless oil: [α]D
25 = −11.2 (c 1.0, CH3Cl). All other data (Rf, 
1
H NMR, 
13
C NMR, IR, LRMS, HRMS, 
HPLC) match those of (+)-1D-21. 
Synthetic protocol and characterisation data for (+)-1D-1-O-((S)-acetylmandelyl)-2-O-allyl-5-O-benzyl-
6-O-methyl-myo-inositol i.e.  (+)-1D-(26); (−)-1D-1-O-((S)-2-hydroxy-2-phenylacetoxy)-2-O-allyl-5-O-
benzyl-6-O-methyl-myo-inositol i.e. (−)-1D-(27) & (−)-1D-2-O-allyl-5-O-benzyl-6-O-methyl-myo-inositol 
i.e. (−)-1D-(19) 
          (+)-1D-(26)  (−)-1D-(27)      (−)-1D-(19) 
To a solution of (+)-1D-21 (30 mg, 0.0473 mmol, 1.0 eq) in MeOH/CH2Cl2 (1:2 v/v) was added acetyl 
chloride (2 μL, 0.0284 mmol, 0.60 eq). The solution was stirred at RT for 19 hours, then neutralised with Et3N 
(4 μL, 0.0284 mmol, 0.60 eq) and the so lvents were concentrated in vacuo. Purification by column 
chromatography over silica gel (Petroleum eth er/EtOAc, 5:5, 4:6, 3:7, 2:8) afforded the expected product 
(+)-1D-26 (4 mg, 17%) as a colourless gum, but also the deacetylated product (−)-1D-27 (11 mg, 32%), and 
the fully deprotected product (−)-1D-19 (6 mg, 37%) as colourless solids: (+)-1D-26: TLC (Petroleum 
ether:EtOAc, 1:1 v/v): Rf = 0.22; [α]D
25 = +17.7 (c 0.27, CH3Cl); 
1
H NMR (400 MHz; CDCl3): δ 7.54–7.48 
(m, 2H, H-21, H-25), 7.43–7.27 (m, 8H, H-22 to H-24 and H-13 to H-17), 5.97 (s, 1H, H-19), 5.57 (dddd, J = 
17.1, 10.5, 5.7, 5.5 Hz, 1H, H-9), 5.02–4.94 (m, 2H, H-10 and H-10’), 4.92 (d, JAB = 11.4 Hz, 1H, H-11), 4.89 
(dd, J = 9.9, 2.6 Hz, 1H, H-1), 4.73 (d, JAB = 11.4 Hz, 1H, H-11’), 3.70 (ddd, J = 9.3, 9.3, 1.5 Hz, 1H, H-4), 
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3.68–3.57 (m, 7H, H-7, H-6, H-2, H-8 and H-8’), 3.42 (ddd, J = 9.3, 6.8, 2.9 Hz, 1H, H-3), 3.25 (dd, J = 9.3, 
9.3 Hz, 1H, H-5), 2.39 (d, J = 1.5 Hz, 1H, C(4)OH), 2.22–2.19 (m, 4H, C(3)OH and H-27); 13C NMR (101 
MHz; CDCl3): δ 170.4 (C-18), 168.4 (C-26), 138.7 (C-12) 134.6 (C-9), 133.6 (C-20), 129.7, 129.1, 128.7, 
128.2, 128.1, 128.0 (C-13 to C-17 and C-21 to C-25), 116.8 (C-10), 82.6 (C-5), 81.4 (C-6), 77.4 (C-2), 75.4 
(C-11), 75.3 (C-1), 74.7 (C-19), 73.9 (C-8), 73.5 (C-4), 71.9 (C-3), 61.3 (C-7), 20.8 (C-27); IR (thin film): 
3426 (O-H) (br), 2930 (w), 1744 (C=O) (s), 1497 (w), 1455 (w), 1372 (m), 1229 (s), 1210 (s), 1180 (m), 1118 
(m), 1048 (s), 924 (m), 738 (m), 698 (s) cm
−1
; LRMS (m/z): [M+Na]
+
 523.2; HRMS (m/z): [M+Na]
+
 calcd. 
for C27H32O9Na, 523.19385; found 523.1936; NP-HPLC (Method 3) tR = 13.21 min, 88.75%; (−)-1D-27: mp: 
145–146 °C; TLC (Petroleum ether:EtOAc, 1:1 v/v): Rf = 0.11; [α]D
25 = −5.16 (c 0.95, CHCl3); 
1
H NMR (400 
MHz; CDCl3): δ 7.46–7.42 (m, 2H, H-21, H-25), 7.40–7.28 (m, 8H, H-22 to H-24 and H-13 to H-17), 5.47 
(dddd, J = 17.1, 10.5, 5.9, 5.5 Hz, 1H, H-9), 5.21 (d, J = 5.1 Hz, 1H, H-19), 5.00–4.95 (m, 1H, H-10), 4.95–
4.88 (m, 1H, H-10’), 4.90 (d, JAB = 11.3 Hz, 1H, H-11), 4.86 (dd, J = 10.3, 2.6 Hz, 1H, H-1), 4.76 (d, JAB = 
11.3 Hz, 1H, H-11’), 3.70 (dd, J = 9.4, 9.4 Hz, 1H, H-4), 3.67–3.60 (m, 2H, H-6 and H-2), 3.58 (s, 3H, H-7), 
3.52 (d, J = 5.1 Hz, 1H, C(19)OH), 3.45–3.38 (m, 3H, H-3, H-8 and H-8’), 3.25 (dd, J = 9.4, 9.4 Hz, 1H, H-5), 
2.43 (d, J = 1.5 Hz, 1H, C(4)OH), 2.22 (d, J = 7.1 Hz, 1H, C(3)OH); 
13
C NMR (101 MHz; CDCl3): δ 173.3 
(C-18), 138.6 (C-12), 138.0 (C-20), 134.5 (C-9), 129.0, 128.9, 128.7, 128.08, 128.05 (C-13 to C-17 and C-22 
to C-24), 127.0 (C-21, C-25), 116.8 (C-10), 82.7 (C-5), 81.2 (C-6), 77.3 (C-2), 76.1 (C-1), 75.4 (C-11), 73.70 
(C-8), 73.65 (C-4), 73.4 (C-19), 71.8 (C-3), 61.4 (C-7); IR (thin film): 3395 (O-H) (br), 2934 (w), 2874 (w), 
1739 (m), 1714 (w), 1453 (w), 1421 (w), 1262 (w), 1206 (w), 1182 (w), 1156 (m), 1143 (m), 1123 (m), 1053 
(s), 1030 (s), 933 (m), 735 (m), 696 (s) cm
−1
; LRMS (m/z): [M+Na]
+
 481.2; HRMS (m/z): [M+Na]
+
 calcd. for 
C25H30O8Na, 481.18329; found 481.1831; NP-HPLC (Method 3) tR = 11.36 min, 99.51%. The data for (−)-1D-
19 are identical to those reported below. 
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Synthetic protocol and characterisation data for (−)-1D-2-O-allyl-3,4-O-(L-1,7,7-trimethylbicyclo-
[2.2.1]hept-2-ylidene)-5-O-benzyl-6-O-methyl-myo inositol i.e. (−)-1D-(20a) & (+)-1L-2-O-allyl-3,4-O-(L-
1,7,7-trimethylbicyclo[2.2.1]hept-2-ylidene)-4-O-methyl-5-O-benzyl-myo inositol i.e. (+)-1L-(20c) 
    (−)-1D-(20a)   (+)-1L-(20c) 
Ground solid NaOH (135 mg, 3.37 mmol, 8.1 eq) was added to a solution of (+)-1D-21 (263 mg, 
0.414 mmol, 1.0 eq) in MeOH (35 mL). The reaction mixture was heated under reflux for 30 minutes, then 
allowed to cool to RT and neutralised by slow addition of solid CO2. The solvent was concentrated in vacuo 
and the residue obtained was purified by column chromatography over silica gel (Petroleum ether/EtOAc 8:2, 
7:3, 6:4, 5:5) to afford (−)-1D-20a (187 mg, 99%) as a colourless oil: TLC (Petroleum ether:EtOAc, 5:5 v/v): 
Rf = 0.44; [α]D
25 = −11.7 (c 0.74, CHCl3); 
1
H NMR (400 MHz; CDCl3): δ 7.34–7.17 (m, 5H, H-13 to H-17), 
5.84 (dddd, J = 17.2 Hz, 10.6, 5.4, 5.2 Hz, 1H, H-9), 5.26–5.18 (m, 1H, H-10), 5.14–5.08 (m, 1H, H-10’), 4.84 
(d, JAB = 11.7 Hz, 1H, H-11), 4.64 (d, JAB = 11.7 Hz, 1H, H-11’), 4.40–4.33 (m, 1H, H-8), 4.13–4.04 (m, 1H, 
H-8’), 4.05–4.00 (m, 1H, H-2), 3.87 (dd, J = 9.7, 9.4 Hz, 1H, H-4), 3.59 (s, 3H, H-7), 3.51–3.44 (m, 1H, H-1), 
3.41 (dd, J = 9.4, 8.9 Hz, 1H, H-5), 3.24 (dd, J = 8.9, 8.7 Hz, 1H, H-6), 3.16 (dd, J = 9.7, 1.2 Hz, 1H, H-3), 
2.43 (d, J = 6.8 Hz, 1H, C(1)OH), 2.11–2.02 (m, 1H, Heq-23), 1.82–1.73 (m, 1H, Hax-20), 1.70–1.58 (m, 2H, 
H-22 and Heq-21), 1.36 (d, J = 13.6 Hz, 1H, Hax-23), 1.34–1.25 (m, 1H, Hax-20), 1.18–1.08 (m, 1H, Hax-21), 
0.98 (s, 3H, C(24)CH3), 0.792 (s, 3H, C(27)CH3), 0.785 (s, 3H, C(24)CH3); 
13
C NMR (101 MHz; CDCl3): δ 
138.8 (C-12), 134.4 (C-9), 128.3 (C-14, C-16), 127.8 (C-13, C-17), 127.5 (C-15), 120.4 (C-18), 117.2 (C-10), 
85.4 (C-6), 80.6 (C-5), 77.3 (C-4), 76.8 (C-3), 73.8 (C-2), 73.3 (C-1), 73.1 (C-8), 72.5 (C-11), 61.7 (C-7), 52.9 
(C-19), 48.3 (C-24), 46.1 (C-23), 45.0 (C-22), 28.9 (C-20), 26.7 (C-21), 20.3, 20.2 (C-25, C-26), 9.7 (C-27); 
IR (thin film): 3426 (O-H) (br), 2933 (m), 1454 (w), 1312 (w), 1262 (w), 1202 (m), 1163 (m), 1088 (s), 1069 
(s), 1032 (s), 949 (m), 926 (m), 777 (w), 740 (m), 698 (m) cm
−1
; LRMS (m/z): [M+H]
+
 459.3 ([M+H]
+
; 
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HRMS (m/z): [M+Na]
+
 calcd. for C27H38O6Na, 481.25606; found 481.25495; RP-HPLC (Method 2) tR = 
29.92 min, 97.42%. 
Similarly, from (−)-1L-21 (253 mg, 0.399 mmol, 1.0 eq) and ground NaOH (129 mg, 3.23 mmol, 
8.1 eq) in MeOH (34 mL), (+)-1L-20c (190 mg, 89%) was obtained as a colourless oil: [α]D
25 = +11.9 (c 0.70, 
CHCl3). All other data (Rf, 
1
H NMR, 
13
C NMR, IR, LRMS, HRMS, HPLC) matched those of the opposite 
enantiomer (−)-1D-20a. 
Synthetic protocol and characterisation data for (−)-1D-2-O-allyl-5-O-benzyl-6-O-methyl-myo-inositol 
i.e. (−)-1D-(19) & (+)-1L-2-O-allyl-5-O-benzyl-6-O-methyl-myo-inositol i.e. (+)-1L-(19) 
                (−)-1D-(19)      (+)-1L-(19) 
Acetyl chloride (13 μL, 0.192 mmol, 0.60 eq) was added to a solution of (−)-1D-20a (147 mg, 
0.321 mmol, 1.0 eq) in MeOH/CH2Cl2 (1.0:1.8 v/v, 2.2 mL). After stirring at RT for 16.5 hours, the reaction 
was quenched with Et3N (27 μL, 0.192 mmol, 0.60 eq) and the solvents were removed in vacuo. The off-white 
solid obtained was then crystallised from EtOAc to give (−)-1D-19 (99 mg, 95%, >95% e.e.) as a colourless 
crystalline solid: [𝛼]D
25 = −15.4 (c 1.0, CHCl3); RP-HPLC (Method 1) tR = 9.05 min, 100%; Chiral HPLC 
(Heptane/IPA 90:10, 0.8 mL.min
−1
, 254 nm) tR = 18.88 min, 2.39% (+)-1L-19, tR = 21.43 min, 97.61% (−)-1D-
19, >95% e.e. All other data (Rf, mp, 
1
H NMR, 
13
C NMR, IR, LRMS, HRMS, Purity) match those of the 
racemic product (±)-19.  
Similarly, by treating (+)-1L-20c (158 mg, 0.345 mmol, 1.0 eq) with acetyl chloride (15.0 μL, 
0.207 mmol, 0.60 eq) in MeOH/CH2Cl2 (0.57:1.0 v/v, 2.4 mL), the opposite enantiomer (+)-1L-19 (103 mg, 
93%, >99% e.e.) was obtained as a colourless crystalline solid: [α]D
25 = +15.9 (c 1.0, CHCl3); Chiral HPLC 
(Heptane/IPA 90:10, 0.8 mL.min
−1
, 254 nm) tR = 19.08 min, 99.99% (+)-1L-19, >99% e.e. (other enantiomer 
not observed, tR = 21.43 min). All other data (Rf, mp, 
1
H NMR, 
13
C NMR, IR, HRMS, Purity) match those of 
the racemic product (±)-19.  
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The key intermediates (−)-1D-19 and (+)-1L-19 were studied using single crystal X-ray diffraction 
(See CIF file).  Raw frame data were collected using an Oxford Diffraction SuperNovaA and the structure 
solved with SuperFlip
15
 and refined with CRYSTALS
16
. In both cases, the Flack x, Hooft y parameter and 
Bayesian probabilities are all strongly indicative of the given enantiomer
17
, however, both structures exhibited 
extremely large displacement ellipsoids. Several datasets were collected at low temperature and at room 
temperature with different thermal treatment, but in all cases, on close inspection of the raw diffraction images 
there was some evidence of diffuse scattering and weak super-lattice reflections believed to be due to 
modulation though the reflections were too weak to integrate.  It is believed that this should have little or no 
influence on the absolute structure determination. X-ray crystallographic data for these compounds is included 
below.  
Synthetic protocol and characterisation data for (−)-1D-2-O-allyl-1,3,4,5-tetra-O-benzyl-6-O-methyl-
myo-inositol i.e. (−)-1D-(28) & (+)-1L-2-O-allyl-1,3,4,5-tetra-O-benzyl-6-O-methyl-myo-inositol i.e. (+)-
1L-(28) 
    (−)-1D-(28)       (+)-1L-(28) 
To a solution of (−)-1D-19 (116 mg, 0.358 mmol, 1.0 eq) in DMF (3.0 mL) at 0 °C was added NaH 
(86 mg, 2.15 mmol, 6.0 eq, 60% dispersion in mineral oil) portionwise. The reaction mixture was stirred at 
0 °C for 10 minutes, warmed to RT  and stirred for a further 30 minutes. After cooling once again to 0 °C, 
BnBr (251 μL, 2.11 mmol, 5.9 eq) was added dropwise. The reaction mixture was stirred for 10 minutes at 
0 °C, then warmed to RT and stirred for 20 hours. The reaction was quenched by addition of H2O (2.0 mL), 
then diluted in EtOAc (5 mL). The layers were separated and the aqueous phase was extracted with EtOAc (4 
× 10 mL). The combined organic layers were washed with H2O (2 × 10 mL), brine (2 × 10 mL), and an 
aqueous solution of LiCl (10% w/v, 2 × 10 mL), then dried (MgSO4), filtered, and concentrated in vacuo. The 
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residue obtained was purified by column chromatography over silica gel (Petroleum ether/EtOAc 9.5:0.5, 9:1, 
8.5:1.5, 8:2) to give (−)-1D-28 (200 mg, 94%) as a colourless solid: mp: 70–72 °C; TLC (Petroleum 
ether:EtOAc, 1:1 v/v): Rf = 0.90; [α]D
25 = −13.4 (c 1.0, CHCl3); 
1
H NMR (400 MHz; CDCl3): δ 7.42–7.29 (m, 
20H, H-13 to H-17, H-20 to H-24, H-27 to H-31 and H-34 to H-38), 5.98 (dddd, J = 17.2, 10.2, 5.5, 5.6 Hz, 
1H, H-9), 5.34–5.26 (m, 1H, H-10), 5.22–5.16 (m, 1H, H-10’), 4.90 (d, JAB = 10.6 Hz, 1H, H-11), 4.86 (s, 2H, 
H-18), 4.82 (d, JAB = 10.6 Hz, 1H, H-11’), 4.65–4.54 (m, 4H, H-25 and H-32), 4.34–4.30 (m, 2H, H-8), 3.99 
(dd, J = 9.5, 9.5 Hz, 1H, H-4), 3.95 (dd, J = 2.2, 2.2 Hz, 1H, H-2), 3.74 (dd, J = 9.5, 9.5 Hz, 1H, H-6), 3.68 (s, 
3H, H-7), 3.36 (dd, J = 9.5, 9.5 Hz, 1H, H-5), 3.31 (dd, J = 9.5, 2.2 Hz, 1H, H-3), 3.22 (dd, J = 9.5, 2.2 Hz, 
1H, H-1); 
13
C NMR (101 MHz; CDCl3): δ 139.1 (C-12, C-19), 138.7, 138.5 (C-26, C-33), 136.0 (C-9), 
128.53, 128.48, 128.4, 128.2, 128.1, 127.8, 127.73, 127.65, 127.6 (C-13 to C-17, C-20 to C-24, C-27 to C-31, 
C-34 to C-38), 116.8 (C-10), 84.0 (C-5), 83.7 (C-6), 81.7 (C-4), 80.9 (C-3), 80.8 (C-1), 75.99 (C-11), 75.97 
(C-18), 74.2 (C-2), 73.5 (C-8), 72.9 (C-32, C-25), 61.5 (C-7); IR (thin film): 2956 (m), 2919 (s), 2851 (m), 
2362 (m), 2338 (m), 1457 (w), 1361 (w), 1261 (w), 1159 (w), 1130 (m), 1090 (s), 1043 (m), 801 (w), 735 (m), 
698 (m) cm
−1
; LRMS (m/z): [M+Na]
+
 617.3; HRMS (m/z): [M+Na]
+
 calcd. for C38H42O6Na, 617.28736; 
found 617.28706; Chiral HPLC (Heptane/IPA 95:5, 1.0 mL.min
−1
, 254 nm) tR = 11.94 min, 99.85%. 
Similarly, (+)-1L-19 (116 mg, 0.357 mmol, 1.0 eq), NaH (86.0 mg, 2.15 mmol, 6.0 eq, 60% 
dispersion in mineral oil), and BnBr (251 µL, 2.11 mmol, 5.9 eq) in DMF (3 mL) afforded (+)-1L-28 (191 mg, 
90%) as a colourless solid: [α]D
25 = +12.3 (c 1.0, CHCl3). All other data (Rf, mp, 
1
H NMR, 
13
C NMR, IR, 
LRMS, HRMS, Purity) match those of the opposite enantiomer (−)-1D-28. 
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Synthetic protocol and characterisation data for (−)-1D-1,3,4,5-Tetra-O-benzyl-6-O-methyl-myo-inositol 
i.e. (−)-1D-(22) & (+)-1L-1,3,4,5-tetra-O-benzyl-6-O-methyl-myo-inositol i.e. (+)-1L-(22) 
   (−)-1D-(22)       (+)-1L-(22) 
To a solution of (−)-1D-28 (182 mg, 0.306 mmol, 1.0 eq) in MeOH/CH2Cl2 (2.5:1.0 v/v, 2.2 mL) was 
added PdCl2 (6.0 mg, 0.0337 mmol, 0.11 eq). The reaction mixture was stirred at RT for 19 hours, then 
diluted in CH2Cl2 (5 mL). The solution was filtered through a short pad of Celite
®
, washed with CH2Cl2 (5 × 
10 mL), and the filtrate was concentrated in vacuo. Purification by column chromatography over silica gel 
(Petroleum ether/EtOAc 8:2, 7:3) afforded (−)-1D-22 (160 mg, 94%) as a colourless oil: TLC (Petroleum 
ether:EtOAc, 7:3 v/v): Rf = 0.32; [α]D
25 = −19.4 (c 0.81, CHCl3); 
1
H NMR (400 MHz; CDCl3): δ 7.41–7.26 (m, 
20H, H-10 to H-14, H-17 to H-21, H-24 to H-28 and H-31 to H-35), 4.91–4.81 (m, 4H, H-8 and H-15), 4.77–
4.66 (m, 4H, H-22 and H-29), 4.19 (dd, J = 2.7, 2.7 Hz, 1H, H-2), 3.95 (dd, J = 9.6, 9.6 Hz, 1H, H-5), 3.70 
(dd, J = 9.6, 9.6 Hz, 1H, H-6), 3.68 (s, 3H, H-7), 3.39–3.32 (m, 2H, H-3 and H-4), 3.28 (dd, J = 9.6, 2.7 Hz, 
1H, H-1), 2.43 (s, 1H, C(2)OH); 
13
C NMR (101 MHz; CDCl3): δ 139.0, 138.9 (C-9, C-16), 138.3, 138.1 
(C-23, C-30), 128.6, 128.49, 128.48, 128.12, 128.11, 128.01, 127.98, 127.96, 127.92, 127.72, 127.69 (C-10 to 
C-14, C-17 to C-21, C-24 to C-28 and C-31 to C-35), 83.4 (C-4), 83.2 (C-6), 81.2 (C-5), 79.9 (C-3), 79.8 
(C-1), 76.1, 76.0 (C-8, C-15), 72.92, 72.85 (C-22, C-29), 67.9 (C-2), 61.5 (C-7); IR (thin film): 3465 (O-H) 
(w), 3063 (w), 3030 (w), 2924 (w), 2878 (w),1497 (w), 1454 (w), 1360 (w), 1128 (m), 1085 (s), 1069 (s), 
1028 (m), 732 (s), 696 (s) cm
−1
; LRMS (m/z): [M+Na]
+
 577.3; HRMS (m/z): [M+Na]
+
 calcd. for C35H38O6Na, 
577.25606; found 577.25541; RP-HPLC (Method 1) tR = 15.95 min, 98.57%. 
Similarly, from (+)-1L-28 (173 mg, 0.291 mmol, 1.0 eq) and PdCl2 (6 mg, 0.0320 mmol, 0.11 eq) in 
MeOH/CH2Cl2 (2.5:1.0 v/v, 2.0 mL), (+)-1L-22 (150 mg, 93%) was obtained as a colourless oil: [α]D
25 = +19.6 
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(c 1.0, CHCl3). All other data (Rf, mp, 
1
H NMR, 
13
C NMR, IR, LRMS, HRMS, Purity) match those of the 
opposite enantiomer (−)-1D-22. 
 
Synthetic protocol and characterisation data for (+)-1D-2,4,5,6-tetra-O-benzyl-3-O-methyl-1-azido-1-
deoxy-scyllo-inositol i.e. (−)-1D-(29) & (−)-1L-2,4,5,6-tetra-O-benzyl-3-O-methyl-1-azido-1-deoxy-scyllo-
inositol i.e. (−)-1L-(29) 
    (+)-1D-(29)       (−)-1L-(29) 
A solution of (−)-1D-22 (250 mg, 0.451 mmol, 1.0 eq) in pyridine (4.0 mL) was cooled to 0 °C. 
Methanesulfonyl chloride (837  μL, 10.8 mmol, 24 eq) was added dropwise and the reaction mixture was 
gradually warmed to RT. After stirring for 20 hours, the reaction was quenched with H2O (3 mL) and diluted 
with CH2Cl2 (3 mL). The aqueous layer was extracted with CH2Cl2 (3 × 5 mL) and the combined organic 
layers were washed with H2O (2 × 3 mL) and brine (2 × 3 mL), then dried (Na2SO4), filtered, and 
concentrated in vacuo. Without any further purification, the yellowish oil obtained was dissolved in DMF (4.0 
mL). NaN3 (214 mg, 3.29 mmol, 7.3 eq) was added and the reaction mixture was heated at 90 °C for 18 hours. 
H2O (3 mL) was added and the aqueous phase was extracted with EtOAc (2 × 5 mL). The combined organic 
layers were washed with H2O (5 mL) and brine (5 mL), then dried (MgSO4), filtered, and concentrated in 
vacuo. The yellow oil obtained was purified by column chromatography over silica gel (Hexane/EtOAc 10:2) 
to give (+)-1D-29 (248 mg, 95%) as a gummy solid: TLC (Petroleum ether:EtOAc, 7:3 v/v): Rf = 0.77; 
[α]D
25 = +11.6 (c 0.82, CHCl3); 
1
H NMR (500 MHz; CDCl3): δ 7.47–7.27 (m, 20H, H-10 to H-14, H-17 to 
H-21, H-24 to H-28 and H-31 to H-35), 4.90–4.81 (m, 8H, H-8, H-15, H-22 and H-29), 3.68 (s, 3H, H-7), 
3.55–3.47 (m, 1H, H-4), 3.47–3.38 (m, 2H, H-1 and H-5), 3.32 (dd, J = 9.7, 9.7 Hz, 1H, H-2 or H-6), 3.28–
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3.22 (m, 2H, H-3 and H-2 or H-6); 
13
C NMR (126 MHz; CDCl3): δ 138.5, 138.05, 137.97 (C-9, C-16, C-23, 
C-30), 128.63, 128.60, 128.57, 128.5, 128.4, 128.2, 128.11, 128.06, 127.9, 127.8 (C-10 to C-14, C-17 to C-21, 
C-24 to C-28 and C-31 to C-35), 85.5 (C-3), 83.2 (C-4), 82.8 (C-5), 81.3 (C-2 or C-6), 81.2 (C-2 or C-6), 
76.11, 76.08, 76.03, 76.02 (C-8, C-15, C-22, C-29), 66.9 (C-1), 61.7 (C-7); IR (thin film): 3031 (w), 2919 
(br), 2105 (N3) (m), 1497 (w), 1454 (w), 1359 (w), 1264 (w), 1137 (m), 1063 (s), 1027 (m), 735 (m), 697 (s) 
cm
−1
; LRMS (m/z): [M+K]
+
 618.3; HRMS (m/z): [M+Na]
+
 calcd. for C35H37O5N3Na, 602.26254; found 
602.26233. The data are in good agreement with the literature values for racemic (±)-29
13,14
. 
Similarly, the reaction of (+)-1L-22 (300 mg, 0.541 mmol, 1.0 eq) and methanesulfonyl chloride 
(1.00 mL, 13.0 mmol, 24 eq) in pyridine (4.8 mL), followed by aqueous work-up, gave a residue which was 
dissolved in anhydrous DMF (4.8 mL). NaN3 (257 mg, 3.95 mmol, 7.3 eq) was added and the reaction mixture 
was heated at 90 °C for 18 hours. Aqueous work-up and purification by column chromatography over silica 
gel (Hexane/EtOAc 10:2) yielded (−)-1L-29 (280 mg, 89%) as a gummy solid: [α]D
25 = −12.5 (c 1.0 in CHCl3). 
All other data (Rf, 
1
H NMR, 
13
C NMR, IR, LRMS, HRMS) match those of the opposite enantiomer (+)-1D-29 
and those of the literature values for racemic racemic (±)-29
13,14
.  
Synthetic protocol and characterisation data for (−)-1D-2,4,5,6-tetra-O-benzyl-3-O-methyl-scyllo-
inosamine i.e. (−)-1D-(30) & (+)-1L-2,4,5,6-tetra-O-benzyl-3-O-methyl-scyllo-inosamine i.e. (+)-1L-(30) 
    (−)-1D-(30)     (+)-1L-(30) 
To a solution of the azide (+)-1D-29 (232 mg, 0.400 mmol, 1.0 eq) in THF (6.3 mL) were added PPh3 
(210 mg, 0.801 mmol, 2.0 eq) and H2O (272 µL). The solution was stirred at 40 °C for 28 hours then cooled to 
RT. The volatile components were concentrated in vacuo. EtOAc (10 mL) and H2O (5 mL) were added to the 
residue obtained. The aqueous layer was extracted with EtOAc (3 × 8 mL) and the combined organic layers 
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were washed with H2O (8 mL), and brine (8 mL), then dried (Na2SO4), filtered, and concentrated in vacuo. 
Purification by column chromatography over silica gel (Petroleum ether/EtOAc/Et3N 9:0.95:0.05, 8:1.95:0.05, 
7:2.95:0.05, 6:3.95:0.05) yielded (−)-1D-30 (134 mg, 60%) as a colourless, glassy solid: mp: 85–88 °C; TLC 
(Petroleum ether:EtOAc, 1:1 v/v): Rf = 0.36; [α]D
25 = −5.2 (c 2.0, CHCl3); 
1
H NMR (500 MHz; CDCl3): δ 
7.51–7.05 (m, 20H, H-10 to H-14, H-17 to H-21, H-24 to H-28 and H-31 to H-35), 4.943 (d, JAB = 10.9 Hz, 
1H, H-22 or H-29), 4.940 (d, JAB = 10.9 Hz, 1H, H-22 or H-29), 4.88 (d, JAB = 10.8 Hz, 1H, H-15), 4.85 (d, 
JAB = 10.6 Hz, 1H, H-8), 4.82 (d, JAB = 10.6 Hz, 1H, H-8’), 4.79 (d, JAB = 10.8 Hz, 1H, H-15’), 4.66 (d, J = 
10.9 Hz, 1H, H-22’ or H-29’), 4.65 (d, J = 10.9 Hz, 1H, H-22’ or H-29’), 3.65 (s, 3H, H-7), 3.53 (dd, J = 9.5, 
9.1 Hz, 1H, H-5), 3.47 (dd, J = 9.1, 8.9 Hz, 1H, H-4), 3.30 (dd, J = 9.7, 9.5 Hz, 1H, H-6), 3.27 (dd, J = 9.1, 8.9 
Hz, 1H, H-3), 3.23 (dd, J = 9.5, 9.1 Hz, 1H, H-2), 2.85 (dd, J = 9.7, 9.5 Hz, 1H, H-1), 1.81 (br s, 3H, 
C(1)NH2); 
13
C NMR (126 MHz; CDCl3): δ 138.6, 138.55, 138.45 (C-9, C-16, C-23, C-30), 128.71, 128.68, 
128.6 (C-11, C-13, C-18, C-20, C-25, C-27, C-32, C-34), 128.2, 128.1, 128.04, 128.00, 127.95, 127.86, 127.8 
(C-10, C-12, C-14, C-17, C-19, C-21, C-24, C-26, C-28, C-31, C-33, C-35), 86.5 (C-3), 84.2 (C-5), 83.7 (C-
4), 83.00, 82.98 (C-2, C-6), 76.1 (C-8), 75.94 (C-15), 75.86, 75.85 (C-22, C-29), 61.4 (C-7), 55.3 (C-1); IR 
(thin film): 3378 (N-H) (w), 3064 (w), 3030 (w), 2903 (w), 2360 (w), 2341 (w), 1581 (N-H) (w), 1497 (m), 
1453 (m), 1353 (m), 1213 (w), 1150 (m), 1133 (m), 1065 (s), 1047 (s), 1027 (s), 940 (w), 803 (s), 753 (m), 
735 (s), 695 (s), 661 (m), 626 (m) cm
−1
; LRMS (m/z): [M+H]
+
 554.3; HRMS (m/z): [M+H]
+
 calcd. for 
C35H40O5N, 554.29010; found 554.28939; RP-HPLC (Method 1) tR = 13.14 min, 95.81%. 
Similarly, from the azide (−)-1L-29 (261 mg, 0.450 mmol, 1.0 eq), PPh3 (236 mg, 0.900 mmol, 
2.0 eq) and H2O (306 µL) in THF (7.1 mL), (+)-1L-30 (136 mg, 63%) was obtained as a colourless, glassy 
solid: [α]D
25 = +4.7 (c 1.7, CHCl3). All other data (Rf, 
1
H NMR, 
13
C NMR, IR, LRMS, HRMS) match those of 
the opposite enantiomer (−)-1D-30.  
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Synthetic protocol and characterisation data for (+)-1D-3-O-methyl-scyllo-inosamine hydrochloride i.e. 
(+)-1D-(2) & (−)-1L-3-O-methyl-scyllo-inosamine hydrochloride i.e. (−)-1L-(2) 
(+)-1D-(2)          (−)-1L-(2) 
To a solution of the protected amine (−)-1D-30 (136 mg, 0.246 mmol, 1.0 eq) in CH2Cl2/MeOH/H2O 
(3:2:1 v/v/v, 3.6 mL) was added 10% Pd/C (42 mg, 0.0393 mmol, 0.16 eq) and molecular biology grade 
concentrated HCl (23 µL) under N2(g). The flask was purged with 3 balloons of H2(g), and the suspension was 
stirred at RT, under H2(g) for 20 hours. The reaction mixture was then filtered through a glass microfiber filter 
and washed with H2O (5 × 5 mL). The filtrate was lyophilised to give a yellowish amorphous solid. The 
colourless solid obtained was dissolved in the minimal amount of H2O (0.5 mL) and loaded onto a pre-washed 
DOWEX
®
 50WX8 cation ion exchange column (∼0.9 mL of resin). The column was eluted with H2O 
(10 mL), then with a 0.10 M aqueous solution of HCl (10 mL). The fractions were combined and lyophilised 
to give the hydrochloride salt (+)-1D-2 (43 mg, 72%) as a colourless solid: decomp. 290–291 °C; [α]D
25 = +2.6 
(c 2.0 in CHCl3); 
1
H NMR (500 MHz; D2O): δ 3.67–3.59 (m, 4H, H-2 and H-7), 3.55–3.49 (m, 1H, H-4), 
3.47–3.40 (m, 2H, H-5 and H-6), 3.22 (dd, J = 8.4, 8.4 Hz, 1H, H-3), 3.13 (dd, J = 10.5, 10.5 Hz, 1H, H-1); 
13
C NMR (126 MHz; D2O): δ 84.0 (C-3), 74.1 (C-5), 72.5 (C-6), 69.7 (C-4), 69.3 (C-2), 60.3 (C-7), 55.6 
(C-1); LRMS (m/z): [M+H]
+
 194.2; HRMS (m/z): [M+H]
+
 calcd. for C7H16O5N, 194.10230; found 
194.10254; GC-MS (derivatised with TMSI) tR = 15.97 min, 97.27%. The data are in good agreement with the 
literature values for (±)-2
13,14
. 
Similarly, reaction of (+)-1L-30 (158 mg, 0.285 mmol, 1.0 eq) and 10% Pd/C (49 mg, 0.0457 mmol, 
0.16 eq) in CH2Cl2/MeOH/H2O (3:2:1 v/v/v, 4.3 mL) and under H2(g), yielded (−)-1L-2 (53.6 mg, 77%) as a 
colourless solid: [α]D
25 = −2.2 (c 2.0, CHCl3). All other data (mp, 
1
H NMR, 
13
C NMR, LRMS, HRMS) match 
those of the opposite enantiomer (+)-1D-2. 
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Synthetic protocol and characterisation data for (±)-2-keto-1,3,4,5-tetra-O-benzyl-6-O-methyl-myo-
inositol i.e. (±)-(23) 
(±)-(23) 
A solution of anhydrous DMSO (196 µL, 2.76 mmol, 2.2 eq) in anhydrous CH2Cl2 (0.40 mL) was 
added dropwise over 5 minutes to a solution of oxalyl chloride (117 µL, 1.38 mmol, 1.1 eq) in CH2Cl2 (2.0 
mL) at −60 °C. A solution of (±)-22 (695 mg, 1.25 mmol, 1.0 eq) in anhydrous CH2Cl2 (1.6 mL) was then 
added dropwise to the reaction mixture and the solution was stirred for a further 2.5 hours, maintaining the 
temperature between −60 °C and −55 °C. Anhydrous Et3N (803 µL, 5.76 mmol, 4.6 eq) was then added and 
the reaction was stirred for a further 5 minutes before warming up to RT. After 1 hour, H2O (3 mL) was added 
and the reaction mixture was diluted in CH2Cl2 (6 mL). The organic phase was separated and the aqueous 
layer was extracted with CH2Cl2 (3 × 6 mL). The combined organic layers were washed with brine (6 mL) and 
H2O (6 mL), then dried (MgSO4), filtered, and concentrated in vacuo. Purification by column chromatography 
over silica gel (Petroleum ether/EtOAc 9.5:0.5, 9:1, 8:2, 7:3) followed by crystallisation from Et2O afforded 
(±)-23 (320 mg, 46%) as a colourless solid: m.p. 97–99 °C; TLC (Petroleum ether:EtOAc, 7:3, v/v): Rf = 
0.86; 
1
H NMR (500 MHz; CDCl3): δ 7.43–7.27 (m, 20H, H-10 to H-14, H-17 to H-21, H-24 to H-28 and H-31 
to H-35), 4.91–4.83 (m, 5H, H-8, H-15, H-22 and H-29), 4.76 (d, JAB = 10.6 Hz, 1H, H-8’), 4.58 (d, JAB = 11.7 
Hz, 1H, H-29’), 4.53 (d, JAB = 11.5 Hz, 1H, H-22’), 4.12 (dd, J = 9.8, 1.5 Hz, 1H, H-3), 4.04 (dd, J = 9.9, 1.5 
Hz, 1H, H-1), 3.77 (dd, J = 9.4, 9.3 Hz, 1H, H-5), 3.65 (s, 3H, H-7), 3.57 (dd, J = 9.8, 9.4 Hz, 1H, H-4), 3.32 
(dd, J = 9.9, 9.3 Hz, 1H, H-6); 
13
C NMR (126 MHz; CDCl3): δ 202.2 (C-2), 138.4, 138.3 (C-9, C-16), 137.6 
(C-30), 137.5 (C-23), 128.6, 128.55, 128.52, 128.3, 128.21, 128.19, 128.11, 128.08, 127.93, 127.91 (C-10 to 
C-14, C-17 to C-21, C-24 to C-28, C-31 to C-35), 83.8 (C-3), 83.7 (C-1), 83.5 (C-6), 82.4 (C-5), 81.5 (C-4), 
76.25 (C-15), 76.16 (C-8), 73.5 (C-29), 73.4 (C-22), 61.8 (C-7); IR (thin film): 3063 (w), 3031 (w), 2909 (w), 
2867 (w), 1731 (C=O) (m), 1497 (w), 1454 (w), 1360 (w), 1214 (w), 1133 (m), 1065 (s), 1026 (s), 970 (m), 
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921 (w), 754 (m), 732 (m), 695 (s) cm
−1
; LRMS (m/z): [M+Na]
+
 575.2; HRMS (m/z): [M+Na]
+
 calcd. for 
C35H36O6Na, 575.24041; found 575.24020; RP-HPLC (Method 2) 16.01 min, 99.80%.  
Synthetic protocol and characterisation data for (±)-3-O-Methyl-scyllo-inosose i.e. (±)-6 
     (±)-6           (±)-31 
To a solution of (±)-23 (27 mg, 0.0494 mmol, 1.0 eq) in MeOH/CH2Cl2/H2O/AcOH (5:2:1:1 v/v/v/v 3.6 mL) 
was added 10% Pd/C (7 mg, 0.00658 mmol, 0.13 eq) under N2(g). The flask was purged with 3 balloons of 
H2(g), and the suspension was stirred at RT, under H2(g) for 17 hours. The reaction mixture was then filtered 
through a microfibre glass filter and washed with H2O (3 × 2 mL). The filtrate was lyophilised to give (±)-6 (8 
mg, 84%) as a colourless solid. This compound was found to be very unstable, and in equilibrium with the 
hydrate form (±)-31 as observed by 
1
H NMR ((±)-6 (Ket.)/(±)-31 (Diol) 1.3:1.0). As a result, clean 
1
H NMR 
and 
13
C NMR data for this compound could not be obtained. This compounds was made fresh before use in in 
vitro assays: mp: 95–97 °C; TLC (EtOAc:H2O:IPA, 1:1:1 v/v/v): Rf = 0.55; 
1
H NMR (500 MHz; D2O): δ 4.51 
(dd, J = 10.2, 1.6 Hz, 1H, H-2 Ket.), 4.37 (dd, J = 10.3, 1.6 Hz, 1H, H-6 Ket.), 3.89 (dd, J = 9.7, 9.5 Hz, 1H, 
H-4 Ket.), 3.62 (s, 3H, H-7 Ket.), 3.59 (s, 3H, H-7 Diol), 3.50–3.34 (m, 5H, H-5 Ket., H-6, H-5, H-4 and H-2 
Diol), 3.23 (dd, J = 10.2, 9.7 Hz, 1H, H-3 Ket.), 3.24–3.16 (m, 1H, H-3 Diol); 13C NMR (126 MHz; D2O): δ 
205.6 (C-1 Ket.), 94.1 (C-1 Diol), 83.3 (C-3 Ket.), 83.0 (C-3 Diol), 75.9 (C-6 Ket.), 75.5 (C-2 Ket.), 74.1 (C-6 
Diol), 73.7 (C-2 Diol), 73.6 (C-5 Ket.), 73.14, 73.07 (C-5, C-4 Diol), 72.3 (C-4 Ket.), 59.8 (C-7 Diol), 59.7 
(C-7 Ket.); IR (thin film): 3089 (w), 3063 (w), 3030 (w), 2911 (w), 2867 (w), 1731 (C=O) (m), 1497 (w), 
1454 (m), 1361 (m), 1215 (w), 1133 (s), 1065 (s), 1035 (s), 1026 (s), 970 (m), 921 (m), 754 (s), 734 (s), 695 
(s) cm
−1
; LRMS (m/z): [2M+Na]
+
 407.2 (Ket.); [2M+H]
+
 421.0 (Diol); HRMS (Ket.) m/z (ESI
−
) found 
227.03279 [M+Cl]
−
 (C7H12O6Cl requires 227.03279 [M+Cl]
−
); HRMS (m/z): [M+Cl]
−
 calcd. for C7H14O7Cl, 
245.04335; found 245.04314. The data are in good agreement with the literature values.
18
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Supplementary Table 1. Bacterial strains 
Organism Description/Genotype Source 
Agrobacterium tumefaciens 
GV3101:pM
P90 
C58 pMP90(pTiC58DT-DNA), Gm
R
, Rf
R
 
19
 
AGL1 C58 recA pTiBo542DT-DNA, Rf
R
, Carb
R
 
20
 
Agrobacterium rhizogenes 
AR1193 C58 pRi1193 carrying pBR322 Rf
R
, Carb
R     
 
21
 
Escherichia coli 
DH5-α F– endA1 glnV44 thi-
1 recA1 relA1 gyrA96 deoR nupG purB20 φ80dlacZΔM15 
Δ(lacZYA-argF)U169, hsdR17(rK
–
mK
+), λ– 
Bioline 
BL21 
(DE3) 
F
–
 ompT gal dcm lon hsdSB(rB
–
mB
–) λ(DE3 [lacI lacUV5-
T7p07 ind1 sam7 nin5]) [malB
+
]K-12(λ
S
) 
Bioline 
Rhizobium leguminosarum 
3841 Wild-type, St
R
 
22
 
UPM1137 Wild-type 
23
 
OPS1341 3841 with mCherry3 expression cassette integrated into genome 
by Tn7, St
R
, Gm
R
 
 
  
Jorrin 
Rubio et al. 
in 
preparation. 
Sinorhizobium meliloti 
BL225C Wild-type 
24
 
CO431A Wild-type 
25
 
L5-30 Wild-type, St
R
 
26
 
OPS0646 L5-30 mosB::pK19, St
R
, Nm
R
 This work 
OPS0648 L5-30 mosE::pK19, St
R
, Nm
R
 This work 
Rm1021 Wild-type, St
R
 
27
 
SM11 Wild-type  
28
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Supplementary Table 2. Bacterial plasmids 
Name Description/Genotype Reference 
pMQ131 Yeast gap repair cloning compatible plasmid, Km
R
 
29
 
pOGG024 Level 1 golden gate cloning destination vector for free-living 
expression, Gm
R
 
pL1V-gent-pBBR1-ELT3, Gm
R
 
30 
pOPINF Cloning vector for T7RNAP based protein purification in E. coli, 
Amp
R
 
31
 
pIJ11268 Cloning vector for construction of lux reporters that are stable in 
the environment, Tc
R
 
32
 
pOPS0046 pIJ11268 mocRBluxCDABE rhizopine lux reporter, Tc
R
 This work 
pOPS0241 pOPINF iolG, for IolG purification from BL21, Amp
R
 This work 
pOPS0243 pK19 mosB, for integration into L5-30 mosB, Km
R
 This work 
pOPS0244 pK19 mosE for integration into L5-30 mosE, Km
R
 This work 
pOPS0362 pMQ131par mosDEF, for stable nodule expression of rhizopine 
synthesis genes, Km
R
 
This work 
pOPS0363 pOGG024 MBP-mosB, for MosB purification from R. 
leguminosarum, Gm
R
 
This work 
pOPS0761 pMQ131par mocRBGFPmut3 rhizopine GFP reporter, Km
R
 This work 
pRK2013 Self transmissible helper plasmid, Km
R
 
33
 
pTNS3 Plasmid expressing tnsABCD from P1 and Ptac 
34
 
pUC18T-
miniTn7T-
Gm 
For Tn7 insertion into Gm
S
 bacteria, Amp
R
, Gm
R
 
35,36
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Supplementary Table 3. Plant transformation plasmids 
Plasmid Description Reference 
pEC50505 Level 2 cloning vector for plant engineering, Km
R 
 
37
 
pEC11281 EC50505-eGFP, for plant transient transformation, Km
R
 This work 
pEC12824 EC50505-eGFP-mosA-mosB-mosC, for plant transient 
transformation, Km
R
 
This work 
pEC12805 EC50505-eGFP-IMT-mosDEF-mosB, for plant transient 
transformation, Km
R
 
This work 
pEC11910 EC50505-eGFP-IDH, for plant transient transformation, Km
R
 This work 
pEC11906 EC50505-eGFP-mosB, for plant transient transformation, Km
R
 This work 
pEC11912 EC50505-eGFP-IDH-mosB, for plant transient transformation, 
Km
R
 
This work 
pEC12825 EC50505-HYG, for barley stable transformation, Km
R
 This work 
pEC12811   EC50505-HYG-IDH-mosB, for barley stable transformation, 
Km
R
 
This work 
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Supplementary Table 4. Primers 
Primer Sequence (5’ 3’) Description 
oxp0024 AGGAGGAAGAACATATGATGTTTGAGGGTT
CGATTAC 
Forward primer for amplification of mosABC ORFs 
for cloning into pLMB509 by Infusion BD cloning 
oxp0053 TGGTGATGATGCATATGTCAAGGCTCTGGC
TGGCC 
Reverse primer for amplification of mosABC ORFs 
for cloning into pLMB509 by Infusion BD cloning 
oxp0069 ATATGGATCCTCAGTTCTTTCCCTGAAACTC
G 
Foreword primer for amplification of mocRB ORFs 
for cloning into pIJ11268 BamH1 site 
oxp0070 ATATGGATCCTCAGCAACCACGTGGAGCAG Reverse primer for amplification of mocRB ORFs for 
cloning into pIJ11268 BamH1 site 
oxp0558 AAGTTCTGTTTCAGGGCCCGATGAGTTTAC
GTATTGGC 
Foreword primer for amplification of iolG ORF for 
cloning into pOPINF by Infusion BD cloning 
oxp0559 CTGGTCTAGAAAGCTTTAGTTTTGAACTGTT
GTAAAAG 
Reverse primer for amplification of iolG ORF for 
cloning into pOPINF by Infusion BD cloning 
oxp0560 TGATTACGCCAAGCTTTGTGGTCTCGGCAA
GTAGC 
Foreword primer for amplification of mosB internal 
fragment for cloning into pK19 by Infusion BD 
cloning 
oxp0561 GCAGGCATGCAAGCTTCGCGGAAAACGGCA
TAACC 
Reverse primer for amplification of mosB internal 
fragment for cloning into pK19 by Infusion BD 
cloning 
oxp0564 TGATTACGCCAAGCTTAGGGGGAAGGTGAC
TAACGA 
Foreword primer for amplification of mosE internal 
fragment for cloning into pK19 by Infusion BD 
cloning 
oxp0565 GCAGGCATGCAAGCTTCTTGAGAGCGGGTC
ATACGG 
Reverse primer for amplification of mosE internal 
fragment for cloning into pK19 by Infusion BD 
cloning 
oxp0555 TTAGAGTCACTAAGGGCTAACTAACTAATT
ACGTAGAATTCACGTCGCTTCAG 
Foreword primer for amplification of PmosB for 
yeast recombineering with mosDEF in pMQ131par. 
oxp0576 GTGGGCGCCAAGGGTTCGCGCATGGGATGA
GGCATATTACCCCCATGTC 
Reverse primer for amplification of PmosB for yeast 
recombineering with mosDEF in pMQ131par. 
oxp0552 TCATCCCATGCGCGAAC Foreword primer for amplification of mosDEF for 
yeast recombineering with PmosB in pMQ131par. 
oxp0578 CGTAGGGCGCATTAATGCAGCTGGCACGAC
AGGTGAATTCCGAAATTGCCTAAGGTGCC 
Reverse primer for amplification of mosDEF for 
yeast recombineering with PmosB in p pMQ131par 
oxp1436 CCCCTCAAGACCCGTTTAGAGGCCCCAATC
TAGATCTTTGGGACATGCGATCGTATTGCCT
ATG 
 
Reverse primer for amplification of GFPmut3.1 for 
yeast recombineering with mocRB in pMQ131par 
oxp1800 TAGCCCTTAGTGACTCTAATACGACTCACTA
TTGGGAGATTCAGCAACCACGTGGAGC 
 
Forward primer for amplification of mocRB for yeast 
recombineering with  GFPmut3.1  in pMQ131par 
oxp1801 AAAAACGGGTATGGAGAAGGATCCTCAGTT
CTTTCCCTGAAACTCGG 
 
Reverse primer for amplification of mocRB for yeast 
recombineering with  GFPmut3.1  in pMQ131par 
oxp1802 AGTTTCAGGGAAAGAACTGAGGATCCTTCT
CCATACCCGTTTTTTTGGGCT 
 
Forward primer for amplification of GFPmut3.1 for 
yeast recombineering with mocRB in pMQ131par 
GFP F TGTTTGAACGATCTGCTTGACA Forward primer for verification of GFP CDS in 
recombinant plasmid by PCR 
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GFP R CAAGCTGACCCTGAAGTTCATCT Reverse primer for verification of GFP CDS in 
recombinant plasmid by PCR 
mosA F ATCCTCTCAGCGAACCTAGC Forward primer for verification of mosA CDS in 
recombinant plasmid by PCR 
mosA R TGCCCTAACGTTAAGGGTGT Reverse primer for verification of mosA CDS in 
recombinant plasmid by PCR 
mosB F CACGATGAAAGAGTTCTCGATAGC Forward primer for verification of mosB CDS in 
recombinant plasmid by PCR 
mosB R CATCTCTCCTACCGCTCTCG Reverse primer for verification of mosB CDS in 
recombinant plasmid by PCR 
mosC F AGCCATTCCAAGTCCAAGGA Forward primer for verification of mosC CDS in 
recombinant plasmid by PCR 
mosC R ATCTACCGGAATCCTCGCTG     Reverse primer for verification of mosC CDS in 
recombinant plasmid by PCR 
IDH F CCGTAGGTAGCCCTTCTAGAGTTAG Forward primer for verification of idhA CDS in 
recombinant plasmid by PCR 
IDH R GATCGGAAAGGTTCACGCTAA Reverse primer for verification of idhA CDS in 
recombinant plasmid by PCR 
IMT F CTCGCATATCTCATTAAAGCAGG Forward primer for verification of imt CDS in 
recombinant plasmid by PCR 
IMT R CAGATCGGAGCTAAGAACCCTA Reverse primer for verification of imt CDS in 
recombinant plasmid by PCR 
mosD F TCATATCTTGCACCAGGGAATC Forward primer for verification of mosD CDS in 
recombinant plasmid by PCR 
mosD R CGTCGTGAATTGCTTTTCCG Reverse primer for verification of mosD CDS in 
recombinant plasmid by PCR 
mosE F GCTCCGATGAATGGGTTGAT Forward primer for verification of mosE CDS in 
recombinant plasmid by PCR 
mosE R TGGAATCGCTGGAAAGGCTG Reverse primer for verification of mosE CDS in 
recombinant plasmid by PCR 
mosF F CTTCTGGTTGAATGGAGGCAT Forward primer for verification of mosF CDS in 
recombinant plasmid by PCR 
mosF R GGAGTGGCTGTGATCGCTAC Reverse primer for verification of mosF CDS in 
recombinant plasmid by PCR 
HYG F TGCATCATCGAAATTGCCGT Forward primer for verification of hyg CDS in 
recombinant plasmid by PCR 
HYG R CGATTGCTGATCCCCATGTG Reverse primer for verification of hyg CDS in 
recombinant plasmid by PCR 
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Supplementary Table 5. Determination of the absolute configuration of (−)-1D-(20a) using       
α-methoxyphenylacetic acid as a chiral anisotropy reagent.  
 
 
 
Position δ
R (−)-25 δS (+)-25b ΔδRSa L1 or L2 
1 4.75 4.83 −0.08 N/A 
2 4.18 3.95 0.23 L2 
3 3.26 3.22 0.04 L2 
4 3.94 3.93 0.01 N/A 
5 3.45 3.51 −0.06 L1 
6 3.46 3.59 −0.13 L1 
7 3.06 3.52 −0.46 L1 
8c 4.23 3.89 0.34 L2 
8’c 4.00 3.59 0.41 L2 
9 5.80 5.46 0.34 L2 
10b 5.27 5.05 0.22 L2 
10’b 5.15 4.98 0.17 L2 
aCalculation of the differences in chemical shifts ΔδRS for relevant protons 
signals in the 
1
H NMR of (+)-1D-25 and (−)-1D-25. The absolute 
stereochemistry was determined using the Trost conformational model
38–40
 and 
confirmed through single crystal X-ray diffraction as per the CIF..
b
The chemical 
shift (δ) values quoted were obtained from a 1H NMR spectra, run at 400 MHz, 
in CH3Cl. 
c
For multiplets, the middle of the multiplet is quoted, if the peaks 
were not distinguishable, HSQC was employed to assign each chemical shift. 
Me = methyl; Ph = phenyl 
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Supplementary Table 6.  Reverse phase HPLC gradient for Method 1 and Method 2  
 
Step length 
(min) 
Elapsed time 
(min) 
%A %B 
1 1 100 0 
10 11 0 100 
3 14 0 100 
1 15 100 0 
5 20 100 0 
 
 
Supplementary Table 7.  Normal phase HPLC gradient for Method 3 
 
 
 
 
 
 
 
 
 
Step length 
(min) 
Elapsed time 
(min) 
%A %B 
1 1 95 5 
12 13 5 95 
5 18 5 95 
1 19 95 5 
6 25 95 5 
 44 
 
Supplementary Figure 1. Response of rhizopine lux biosensor to Medicago sativa rhizosphere. 
Bioluminescence response measured from R. leguminosarum Rlv3841/pOPS0046 rhizopine lux 
biosensor on the surface of M. sativa roots nodulated by S. meliloti L5-30 Wild-type (rhizopine +) 
and S. meliloti L5-30 mosB:pK19 (rhizopine –), see Figure 2a). NightOwl images are presented, 
with magnified root sections bearing nodules from five sets of plants (one representative set of plants 
presented in Figure 1b). Magnified images show photo only (left), or photo overlayed with 
luminescence response (right). Arrowheads indicate positions of nodules.  Scale of all images is from 
0 to 250 cps.  
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Supplementary Figure 2. Synthesis of SIA (1). 
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a. CH3ClO2S, 
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Supplementary Figure 3. Synthesis of both enantiomers of 3-O-MSI (+)-1D-2 and (+)-1L-2 and 
racemic 3-O-methyl-scyllo-inosose 6. All = allyl, Bn = benzyl; Me = methyl; Ac = acetate; AMA = 
acetylmandelic acid; PMB = 4-methoxybenzyl; CDA = Camphor dimethyl acetal. 
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Supplementary Figure 4. Growth of S. meliloti L5-30 using chemically synthesised rhizopines.  
Growth of S. meliloti L5-30 measured by OD
600 
in UMS minimal media. Media contained either 10 
mM myo-inositol 3 and 10 mM NH4Cl, 10 mM enantiomerically pure or 10 mM racemic 3-O-MSI 2 
as sole carbon and nitrogen sources. Error bars represent standard deviation of three independent 
replicates. 
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Supplementary Figure 5. Putative rhizopine loci in rhizobia. 
a. Structure of putative rhizopine loci with MosB homologues in rhizobia with sequenced genomes.  
b. GC-MS TIC chromatograms from nodules formed by rhizobia with putative rhizopine loci. (±)-3-
O-methyl scyllo-inosamine (±)-2 (red) production was observed based on comparison with a 
chemical standard. SIA 1 production was not observed. Source data of Supplementary Figure 5b are 
provided as a Source Data file.  
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Supplementary Figure 6. Glutamate serves as amino donor to MosB. 
a. Quantification of 3-O-MSI 2 production from (±)-3-O-methyl-scyllo-inosose (±)-6 by MosB in 
vitro assay with different amino donors b. Quantification of SIA 1 production from myo-inositol by 
IolG + MosB linked in vitro assay with different amino donors. Error bars represent standard 
deviation of three independent replicates. 
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Supplementary Figure 7. Transient expression of 3-O-MSI biosynthesis pathway in N. 
benthamiana leaves.  
GC-MS Chromatograms of extracts prepared from tobacco leaves agro-infiltrated with either empty 
vector (control) or IMT-MosDEF-MosB together. TIC, total ion chromatograms; (+)-1D-ononitol 4 
(light blue); myo-inositol 3 (dark blue). The chromatograms shown are representative of experiments 
repeated at least three independent times. Source data are provided as a Source Data file. 
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Supplementary Figure 8. Transient expression of inositol dehydrogenases in N. benthamiana 
leaves. 
a. GC-MS Chromatograms of extracts prepared from tobacco leaves agro-infiltrated with either 
empty vector (control) or IdhA or IolG. TIC, total ion chromatograms; scyllo-inosose 7 (green); myo-
inositol 3 (dark blue). All chromatograms are representative of experiments repeated at least two 
independent times. b-c. Mass spectra of scyllo-inosose 7 produced in tobacco leaves agro-infiltrated 
with either IdhA (b) or IolG (c). Source data of Supplementary Figure 8a are provided as a Source 
Data file. 
  
8.4 8.6 8.8 9 9.2 9.4 9.6 9.8 10 
Retention time (min) 
  
Empty vector 
     
 
IdhA        
 
IolG 
        
 
Tobacco leaves  
myo-inositol
scyllo-inosose
TIC
5 
x10 
0 
3.0 
4.0 
1.0 
2.0 
191.1 
204.1 
217.1 
265.1 
305.1 
318.1 
180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 
scyllo-inosose (RT - 9.0 min) 
 
Tobacco leaves - IolG 
 
Counts vs Mass to Charge (m/z) 
5 
x10 
0 
3.0 
4.0 
1.0 
2.0 
191.1 
204.1 
217.1 
265.1 
305.1 
318.1 
180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 
Counts vs Mass to Charge (m/z) 
Tobacco leaves - IdhA 
scyllo-inosose (RT - 9.0 min) 
 
a.
b. c.
 52 
 
Supplementary Figure 9. Enzyme activity of purified inositol dehydrogenases 
Enzyme activity of inositol dehydrogenase from Rhizobium leguminosarum (IdhA) (a) or Bacillus 
subtilis (IolG) (b) was measured by NAD
+
-linked inositol dehydrogenase assay with myo-inositol as 
a substrate as previously described
41
.  
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Supplementary Figure 10. EIC[245] chromatograms from transient expression of SIA 
biosynthesis pathway in N. benthamiana leaves. 
GC-MS Chromatograms of extracts prepared from tobacco leaves agro-infiltrated with either empty 
vector (control) or IdhA or MosB or IdhA-MosB together. EIC (m/z 245), Extracted ion 
chromatogram (mass to charge ratio); scyllo-inosamine 1 (orange). All chromatograms are 
representative of experiments repeated at least three independent times.5t 
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Supplementary Figure 11. Rhizopine mediated transkingdom signalling in M. truncatula root 
organ culture expressing synthetic SIA biosynthesis pathway. 
a. GC-MS total ion chromatograms (TIC) of extracts prepared from M. truncatula transgenic hairy 
root cultures transformed with empty vector (control) or IdhA-MosB together. scyllo-inosamine 1 
(orange); scyllo-inosose 7 (green); myo-inositol 3 (dark blue). All chromatograms are representative 
of experiments repeated at least three independent times. b. NightOwl images showing 
bioluminescence of Rlv3841/pOPS0046 rhizopine lux biosensor on the surface of hairy root cultures 
transformed with empty vector (control) or IdhA-MosB together (engineered). Numbers in top right 
corners indicate number of plants tested that showed significant levels of bioluminescence. 
Experiments were repeated at least three independent times. Source data of Supplementary Figure 
11a are provided as a Source Data file. 
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Supplementary Figure 12. Rhizopine lux biosensor response to M. truncatula roots expressing 
inositol dehydrogenase alone. 
NightOwl images showing bioluminescence of Rlv3841/pOPS0046 rhizopine lux biosensor on the 
surface of M. truncatula transgenic roots transformed with IdhA alone (Engineered). Numbers in top 
right corners indicate number of plants tested. Experiments were repeated at least two independent 
times.  
 
0/8 
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2,3,4,5,6-Tetra-O-benzyl-scyllo-inosamine – 13C NMR spectrum 
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Supplementary Figure 14 – 13C NMR (126 MHz; CDCl3) of compound 15  
 
2,3,4,5,6-Tetra-O-benzyl-scyllo-inosamine – 1H NMR spectrum 
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Supplementary Figure 13 – 1H NMR (500 MHz; CDCl3) of compound 15  
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scyllo-Inosamine hydrochloride – 1H NMR spectrum  
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Supplementary Figure 16 – 1H NMR (400 MHz; D2O) of compound 1  
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aj81bisAcquisition Date/Time 12/3/2015 10:52 am Sample Name
Time Area Area %
9.932 138,738 0.62
11.459 21,350,728 95.25
12.201 924,866 4.13
Total 22,414,332 100.00
  12/7/2015 8:49 am
Page 1 Of 1 
 
2,3,4,5,6-Tetra-O-benzyl-scyllo-inosamine – RP-HPLC (Method 1) 
 
BnO
OBn
OBn
OBn
OBnH2N
Supplementary Figure 15 – HPLC trace of compound 15  
Method 1, t = 11. 459 min, 95.25%. 
BnO
OBn
OBn
OBn
OBn
H2N
15
 58 
 
 
 
0
50
100
150
200
250
9 14 19 24 29 34
Ti
tle
x 1
00
00
0
Title
Internal 
standard
Ribitol 
 
scyllo-Inosamine hydrochloride – GC-MS chromatogram (derivatised with TMSI) 
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scyllo-Inosamine hydrochloride – 13C NMR spectrum  
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Supplementary Figure 17 – 13C NMR (126 MHz; D2O) of compound 1  
Supplementary Figure 18 – GS-MS chromatogram of compound 1 (t = 16.8 min, 100%)  
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(±)-4-O-(4-Methoxybenzyl)-6-O-methyl-myo-inositol 1,3,5-orthoformate – 13C NMR spectrum 
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(±)-4-O-(4-Methoxybenzyl)-6-O-methyl-myo-inositol 1,3,5-orthoformate – 1H NMR spectrum 
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Supplementary Figure 20 –  13C NMR (101 MHz; CDCl3) of compound (±)-24 
O O
O
OMe
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HO
(±)-24
Supplementary Figure 19 – 1H NMR (400 MHz; CDCl3) of compound (±)-24 
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(±)-2-O-Allyl-4-O-(4-methoxybenzyl)-6-O-methyl-myo-inositol 1,3,5-orthoformate – 1H NMR spectrum 
 
O O
O
AllO
OMe
PMBO
 
(±)-2-O-Allyl-4-O-(4-methoxybenzyl)-6-O-methyl-myo-inositol 1,3,5-orthoformate – 13C NMR spectrum 
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Supplementary Figure 21 – 1H NMR (400 MHz; CDCl3) of compound (±)-16 
Supplementary Figure 22 – 13C NMR (101 MHz; CDCl3) of compound (±)-16 
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(±)-2-O-Allyl-4-O-(4-methoxybenzyl)-6-O-methyl-myo-inositol 1,3-O-methylene – 1H NMR spectrum 
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(±)-2-O-Allyl-4-O-(4-methoxybenzyl)-6-O-methyl-myo-inositol 1,3-O-methylene – 13C NMR spectrum 
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Supplementary Figure 23 – 1H NMR (400 MHz; CDCl3) of compound (±)-17 
Supplementary Figure 24 – 13C NMR (101 MHz; CDCl3) of compound  (±)-17 
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(±)-2-O-Allyl-5-O-benzyl-4-O-(4-methoxybenzyl)-6-O-methyl-myo-inositol  
1,3-O-methylene – 1H NMR spectrum 
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(±)-2-O-Allyl-5-O-benzyl-4-O-(4-methoxybenzyl)-6-O-methyl-myo-inositol 1,3-O-methylene  
– 1H NMR spectrum 
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Supplementary Figure 25 – 1H NMR (400 MHz; CDCl3) of compound (±)-18 
Supplementary Figure 26 – 13C NMR (101 MHz; CDCl3) of compound (±)-18 
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(±)-2-O-Allyl-5-O-benzyl-6-O-methyl-myo-inositol – 1H NMR spectrum 
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(±)-2-O-Allyl-5-O-benzyl-6-O-methyl-myo-inositol – 13C NMR spectrum 
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Supplementary Figure 27 – 1H NMR (400 MHz; CDCl3) of compound (±)-19 
Supplementary Figure 28 – 13C NMR (101 MHz; CDCl3) of compound (±)-19 
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Time Area Area %
19.585 1,655,418 50.49
22.392 1,623,458 49.51
Total 3,278,876 100.00
  5/27/2016 2:41 pm
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(±)-2-O-Allyl-5-O-benzyl-6-O-methyl-myo-inositol – Chiral HPLC  
(Heptane/IPA 90:10, 0.8 mL.min−1, 254 nm) 
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Supplementary Figure 29 – Chiral HPLC of compound (±)-19. 
Heptane/IPA 90:10, 0.8 mL.min-1, 254 nm, t = 19. 585 min, 
50.49%; t = 22.392, 49.51%. 
AllO
HO
OH
OH
OMe
OBn
(±)-19
3-O_MSI-2ndrunAcquisition Date/Time 5/11/2015 2:26 pm Sample Name
Time Area Area %
12.940 51 0.00
13.062 40 0.00
19.075 2,180,129 99.99
30.681 105 0.00
Total 2,180,325 100.00
  5/11/2015 6:43 pm
Enantiopurity by HPLC
Page 1 Of 1EE determination 90:10 Hep:IPA 254 nm
5-O-MSIAcquisition Date/Time 5/11/2015 3:15 pm Sample Name
Time Area Area %
18.878 86,506 2.39
21.434 3,532,172 97.61
Total 3,618,678 100.00
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(−)-1D-2-O-Allyl-5-O-benzyl-6-O-methyl-myo-inositol & (+)-1L-2-O-allyl-5-O-benzyl-6-O-methyl-myo-inositol 
– Chiral HPLC (Heptane/IPA 90:10, 0.8 mL.min−1, 254 nm) 
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Supplementary Figure 30 – Chiral HPLC of compounds (+)-19 and (−)-19.  
Heptane/IPA 90:10, 0.8 mL.min-1, 254 nm, t = 19. 585 min, 50.49%; t = 22.392, 49.51%. 
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(+)-1D-1-O-((S)-α-methoxyphenylacetoxy)-2-O-allyl-3,4-O-(L-1,7,7-trimethyl[2.2.1]bicyclohept-2-ylidene)- 
5-O-benzyl-6-O-methyl-myo-inositol – 1H NMR spectrum 
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(+)-1D-1-O-((S)-α-methoxyphenylacetoxy)-2-O-allyl-3,4-O-(L-1,7,7-trimethyl[2.2.1]bicyclohept-2-ylidene)- 
5-O-benzyl-6-O-methyl-myo-inositol – 13C NMR spectrum 
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Supplementary Figure 31 – 1H NMR (500 MHz; CDCl3) of compound (+)-1D-25a 
Supplementary Figure 32 – 13C NMR (126 MHz; CDCl3) of compound (+)-1D-25a 
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(−)-1D-1-O-((R)-α-methoxyphenylacetoxy)-2-O-allyl-3,4-O-(L-1,7,7-trimethyl[2.2.1] bicyclohept-2- 
ylidene)-5-O-benzyl-6-O-methyl-myo-inositol – 1H NMR spectrum  
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(−)-1D-1-O-((R)-α-methoxyphenylacetoxy)-2-O-allyl-3,4-O-(L-1,7,7-trimethyl[2.2.1]bicyclohept-2- 
ylidene)-5-O-benzyl-6-O-methyl-myo-inositol – 13C NMR spectrum  
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Supplementary Figure 33 – 1H NMR (400 MHz; CDCl3) of compound (−)-1D-25b 
Supplementary Figure 34 – 13C NMR (101 MHz; CDCl3) of compound (−)-1D-25b 
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(+)-1D-1-O-((S)-Acetylmandelyl)-3,4-O-(L-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylidene)-5-O-benzyl-6-O-methyl-
myo-inositol & (−)-1L-1-O-((R)-acetylmandelyl)-2-O-allyl-3,4-O-(L-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylidene)-
5-O-benzyl-6-O-methyl-myo-inositol – 1H NMR spectrum  
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(+)-1D-1-O-((S)-Acetylmandelyl)-3,4-O-(L-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylidene)-5-O-benzyl-6-O-methyl-
myo-inositol & (−)-1L-1-O-((R)-acetylmandelyl)-2-O-allyl-3,4-O-(L-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylidene)-
5-O-benzyl-6-O-methyl-myo-inositol – 13C NMR spectrum  
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Supplementary Figure 35 – 1H NMR (400 MHz; CDCl3) of compounds (+)-1D-21 
& (−)-1L-21 
Supplementary Figure 36 – 13C NMR (101 MHz; CDCl3) of compounds (+)-1D-21 
& (−)-1L-21 
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(−)-1D-2-O-Allyl-3,4-O-(L-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylidene)-5-O-benzyl-6-O-methyl-myo inositol  
& (+)-1L-2-O-allyl-3,4-O-(L-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylidene)-4-O-methyl-5-O-benzyl-myo inositol  
– 1H NMR spectrum 
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(−)-1D-2-O-Allyl-3,4-O-(L-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylidene)-5-O-benzyl-6-O-methyl-myo inositol  
& (+)-1L-2-O-allyl-3,4-O-(L-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylidene)-4-O-methyl-5-O-benzyl-myo inositol 
– 13C NMR spectrum 
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Supplementary Figure 37 – 1H NMR (400 MHz; CDCl3) of compounds (−)-1D-20a 
& (+)-1L-20c. 
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Supplementary Figure 38 – 13C NMR (101 MHz; CDCl3) of compounds (−)-1D-20a 
& (+)-1L-20c. 
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(−)-1D-2-O-Allyl-3,4-O-(L-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylidene)-5-O-benzyl-6-O-methyl-myo inositol  
& (+)-1L-2-O-allyl-3,4-O-(L-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylidene)-4-O-methyl-5-O-benzyl-myo inositol  
– NOESY spectrum 
 
H-4
C(7)CH3
H-2
H-1
H-3
H-6
H-5
Camphor ring 
C(1)OH
The 2D Nuclear Overhauser Spectrocopy (NOESY) spectrum for (−)-380a, showing a through space
correlation between the axial proton on the 4-position of the inositol ring and the protons on the
camphor chiral auxiliary. The 1H NMR spectrum was acquired at 500 MHz, in CDCl3.
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Supplementary Figure 39 – 2D Nuclear Overhauser Spectroscopy 
(NOESY) spect um for compo nd (−)-1D-20a. The spectrum shows a 
through space correlation between the axial protein on the 4-position of 
the inositol ring and the proton on the camphor chiral auxiliary. 
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(−)-1D-2-O-Allyl-1,3,4,5-tetra-O-benzyl-6-O-methyl-myo-inositol & (+)-1L-2-O-allyl-1,3,4,5-tetra-O-benzyl- 
6-O-methyl-myo-inositol– 1H NMR spectrum 
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(−)-1D-2-O-Allyl-1,3,4,5-tetra-O-benzyl-6-O-methyl-myo-inositol & (+)-1L-2-O-allyl-1,3,4,5-tetra- 
O-benzyl-6-O-methyl-myo-inositol – 13C NMR spectrum 
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Supplementary Figure 40 – 1H NMR (400 MHz; CDCl3) of compounds (−)-1D-28 
& (+)-1L-28 
Supplementary Figure 41 – 13C NMR (101 MHz; CDCl3) of compounds (−)-1D-28 
& (+)-1L-28 
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(−)-1D-1,3,4,5-Tetra-O-benzyl-6-O-methyl-myo-inositol & (+)-1L-1,3,4,5-tetra-O-benzyl-6-O-methyl- 
myo-inositol – 1H NMR spectrum 
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(−)-1D-1,3,4,5-Tetra-O-benzyl-6-O-methyl-myo-inositol & (+)-1L-1,3,4,5-tetra-O-benzyl-6-O-methyl- 
myo-inositol – 13C NMR spectrum 
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Supplementary Figure 42 – 1H NMR (400 MHz; CDCl3) of compounds (−)-1D-22 
& (+)-1L-22 
Supplementary Figure 43 – 13C NMR (101 MHz; CDCl3) of compounds (−)-1D-22 
& (+)-1L-22 
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(+)-1D-2,4,5,6-Tetra-O-benzyl-3-O-methyl-1-azido-1-deoxy-scyllo-inositol &(−)-1-L-2,4,5,6-tetra- 
O-benzyl-3-O-methyl-1-azido-1-deoxy-scyllo-inositol – 1H NMR spectrum 
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(+)-1D-2,4,5,6-Tetra-O-benzyl-3-O-methyl-1-azido-1-deoxy-scyllo-inositol &(−)-1-L-2,4,5,6-tetra- 
O-benzyl-3-O-methyl-1-azido-1-deoxy-scyllo-inositol – 13C NMR spectrum 
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Supplementary Figure 44 – 1H NMR (500 MHz; CDCl3) of compounds (+)-1D-29 
& (−)-1L-29 
Supplementary Figure 45 – 13C NMR (101 MHz; CDCl3) of compounds (+)-1D-29 
& (−)-1L-29 
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(−)-1D-2,4,5,6-Tetra-O-benzyl-3-O-methyl-scyllo-inosamine& (+)-1L-2,4,5,6-tetra-O-benzyl-3-O- 
methyl-scyllo-inosamine – 1H NMR spectrum 
 
BnO
OBn
OBn
OBn
OMe
BnO
OBn
OMe
OBn
OBnH2N H2N
 
(−)-1D-2,4,5,6-Tetra-O-benzyl-3-O-methyl-scyllo-inosamine& (+)-1L-2,4,5,6-tetra-O-benzyl-3-O-methyl- 
scyllo-inosamine – 13C NMR spectrum 
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Supplementary Figure 46 – 1H NMR (500 MHz; CDCl3) of compounds (−)-1D-30 
& (+)-1L-30 
 
Supplementary Figure 47 – 13C NMR (126 MHz; CDCl3) of compounds (−)-1D-30 
& (+)-1L-30 
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aj89-concAcquisition Date/Time 12/3/2015 11:19 am Sample Name
Time Area Area %
10.477 111,715 1.33
13.136 8,063,880 95.81
14.376 104,809 1.25
14.740 135,855 1.61
Total 8,416,259 100.00
  12/7/2015 8:49 am
Page 1 Of 1  
(−)-1D-2,4,5,6-Tetra-O-benzyl-3-O-methyl-scyllo-inosamine 
& (+)-1L-2,4,5,6-tetra-O-benzyl-3-O-methyl-scyllo-inosamine  
– RP-HPLC (Method 1) 
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(+)-1D-3-O-Methyl-scyllo-inosamine hydrochloride & (−)-1L-3-O-methyl-scyllo-inosamine hydrochloride  
– 1H NMR spectrum 
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Supplementary Figure 49 – 1H NMR (500 MHz; D2O) of compounds (+)-1D-2 & 
(−)-1L-2 
 
Supplementary Figure 48 – RP-HPLC trace of compounds (+)-1D-30 
& (−)-1L-30. Method 1, t = 13.136 min, 95.81% 
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(+)-1D-3-O-Methyl-scyllo-inosamine hydrochloride (+)-1D-14 & (−)-1L-3-O-methyl-scyllo-inosamine 
hydrochloride – 13C NMR spectrum 
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(+)-1D-3-O-Methyl-scyllo-inosamine hydrochloride & (−)-1L-3-O-methyl-scyllo-inosamine 
hydrochloride – GC-MS chromatogram (derivatised with TMSI) 
 
Retention time (min) Area 
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Supplementary Figure 50 – 13C NMR (126 MHz; D2O) of compounds (+)-1D-2 & 
(−)-1L-2 
 
Supplementary Figure 51 – GS-MS chromatogram of compound 2. t = 15.971 min, 
97.27%. 
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(±)-2-Keto-1,3,4,5-tetra-O-benzyl-6-O-methyl-myo-inositol – 1H NMR spectrum 
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(±)-2-Keto-1,3,4,5-tetra-O-benzyl-6-O-methyl-myo-inositol – 13C NMR spectrum 
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Supplementary Figure 52 – 1H NMR (500 MHz; CDCl3) of compounds (±)-23 
Supplementary Figure 53 – 13C NMR (126 MHz; CDCl3) of compounds (±)-23 
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(±)-2-Keto-1,3,4,5-tetra-O-benzyl-6-O-methyl-myo-inositol 
– RP-HPLC (Method 2)  
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(±)-3-O-Methyl-scyllo-inosose – 1H NMR spectrum 
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Supplementary Figure 54 – RP-HPLC trace of compound 
(±)-23. Method 1 – t = 16.095 min, 99.80%. 
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Supplementary Figure 55 – 1H NMR (500 MHz; D2O) of compounds (±)-6 
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(±)-3-O-Methyl-scyllo-inosose – 13C NMR spectrum 
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Supplementary Figure 56 – 13C NMR (126 MHz; D2O) of compounds (±)-6 
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